blackwiki - User contributions [en]

Template:AMD Radeon RX 5000

2020-09-05T19:30:20Z

84.250.17.211: Fixup Special:Diff/976904765: Use the proper reference name after first referencing of "videocardz-powercolor-rx-5600-xt-14gbps"

{| class="wikitable center" style="font-size: 85%;"
! rowspan=2 | Model ([[codename]])
! rowspan=2 | Release Date & Price
! rowspan=2 | [[Microarchitecture|Architecture]] & [[Semiconductor device fabrication|Fab]]
! rowspan=2 | Transistors & Die Size
! colspan=2 | Core
! colspan=2 | [[Fillrate]]{{efn|name="boost"}}{{efn|name="texture fill"}}{{efn|name="pixel fill"}}
! colspan=3 | Processing power{{efn|name="boost"}}{{efn|name="FLOPS"}} ([[Floating-point_operations_per_second|GFLOPS]])
! colspan=4 | Memory
! rowspan=2 | {{abbr|TBP|Typical Board Power}}
! rowspan=2 | Bus interface
|-
! Config{{efn|name="cconfig"}}
! Clock{{efn|name="boost"}} ([[Hertz|MHz]])
! Texture ([[texel (graphics)|GT]]/s)
! Pixel ([[pixel|GP]]/s)
! [[Half-precision floating-point format|Half]]
! [[Single precision floating-point format|Single]]
! [[Double precision floating-point format|Double]]
! Size ([[Gigabyte|GB]])
! Bandwidth (GB/s)
! Bus type & width
! Clock ([[transfer (computing)|MT/s]])
|-
! style="text-align:left;" | Radeon RX 5300<ref>{{Cite web|last=|first=|date=|title=Radeon RX 5300|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5300#product-specs|url-status=live|archive-url=|archive-date=|access-date=|website=}}</ref>

(Navi 14 XL)
|August 28th, 2020
| rowspan="10" |[[RDNA 1|RDNA 1.0]] [[TSMC]] [[7 nanometer|7FF]]
| rowspan="5" |{{val|6.4|e=9}} 158 mm2
| rowspan="5" |1408:88:32 22 CU
|1327
1645
|116.8
144.8
|42.46
52.64
|7,474
9,265
|3,737
4632
|233.5
289.5
|3
|168
|GDDR6
96-bit
|14000
|100 W
| rowspan="5" |[[PCIe 4.0]] ×8 (with x16 connector)<ref>{{Cite web|title=Meet the Sapphire Pulse Radeon RX 5500 XT|url=https://www.anandtech.com/show/15206/the-amd-radeon-rx-5500-xt-review/2|access-date=2019-12-12|website=anandtech.com|language=en-US}}</ref>
|-
! style="text-align:left;" | Radeon RX 5300 XT<ref>{{Cite web|last=|first=|date=|title=Radeon RX 5300 XT 4GB GRDDR5 included with some HP PCs|url=https://support.hp.com/sg-en/document/c06476253|url-status=live|archive-url=|archive-date=|access-date=|website=}}</ref>
(Navi 14 XL)
| rowspan="2" |October 7, 2019<ref>{{Cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5500|title=Radeon RX 5500|last=|first=|date=|website=|url-status=live|archive-url=|archive-date=|access-date=}}</ref>
|1670
1845
|146.7
162.4
|53.44
59.04
|9,405 ''10,390''
|4,703 ''5,196''
|293.9 ''324.7''
| rowspan="3" |4
|112
|GDDR5
128-bit
|14000
|100 W
|-
! style="text-align:left;" | Radeon RX 5500<ref name="videocardz5500">{{Cite web|url=https://videocardz.com/82162/amd-announces-radeon-rx-5500-series-with-gddr6-memory|title=AMD announces Radeon RX 5500 Series with GDDR6 memory|date=2019-10-07|website=VideoCardz.com|language=en-US|access-date=2019-10-07}}</ref> (Navi 14 XT)
| rowspan="1" | 1670 ''1845''
| rowspan="1" | 146.7 ''162.4''
| rowspan="1" | 53.44 ''59.04''
| rowspan="1" | 9,405 ''10,390''
| rowspan="1" | 4,703 ''5,196''
| rowspan="1" | 293.9 ''324.7''
| rowspan="3" | 224
| rowspan="3" |[[GDDR6]] 128-bit
| rowspan="3" | 14000
| rowspan="1" | 150 W<ref>{{Cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5500#product-specs|title=AMD Radeon™ RX 5500 Graphics|website=amd.com|language=en-US|access-date=2019-12-12}}</ref>
|-
! style="text-align:left;" rowspan=2 | Radeon RX 5500 XT<ref>{{Cite web|url=https://videocardz.com/newz/amd-radeon-rx-5500-xt-to-launch-at-169-usd-4gb-and-199-usd-8gb|title=AMD Radeon RX 5500 XT to launch at 169 USD (4GB) and 199 USD (8GB)|website=VideoCardz.com|language=en-US|access-date=2019-12-12}}</ref> (Navi 14 XTX)
| rowspan=2 | December 12, 2019 {{nowrap|$169 USD (4GB)}} {{nowrap|$199 USD (8GB)}}
| rowspan=2 | 1717 ''1845''
| rowspan=2 | 151.1 ''162.4''
| rowspan=2 | 54.94 ''59.04''
| rowspan=2 | 9,670 ''10,390''
| rowspan=2 | 4,835 ''5,196''
| rowspan=2 | 302.2 ''324.7''
| rowspan=2 | 130 W<ref>{{Cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5500-xt#product-specs|title=AMD Radeon™ RX 5500 XT Graphics|website=amd.com|language=en-US|access-date=2019-12-12}}</ref>
|-
| 8
|-
! style="text-align:left;" | Radeon RX 5600<ref>{{Cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5600|title=Radeon RX 5600|last=|first=|date=|website=|url-status=live|archive-url=|archive-date=|access-date=}}</ref> (Navi 10 XE)
| rowspan=2 | January 21, 2020 {{nowrap|$200/$279 USD (XT)}}
| rowspan=5 | {{val|10.3|e=9}} 251 mm2
| 2048:128:64 32 CU
| 1375 ''1560''
| 176 ''199.7''
| 88 ''99.84''
| 11,264 ''12,780''
| 5,632 ''6,390''
| 352 ''399.4''
| rowspan=2 | 6
| 288
| rowspan=2 | [[GDDR6]] 192-bit
| 12000
| 150 W
| rowspan=5 | [[PCIe 4.0]] ×16
|-
! style="text-align:left;" | Radeon RX 5600 XT<ref>{{Cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5600-xt|title=Radeon RX 5600 XT|last=|first=|date=|website=|url-status=live|archive-url=|archive-date=|access-date=}}</ref> (Navi 10 XLE)
| rowspan=2 | 2304:144:64 36 CU
| 1375 ''1750''<ref>{{Cite web|url=https://videocardz.com/newz/sapphire-quietly-makes-radeon-rx-5600-xt-pulse-faster|title=Sapphire quietly makes Radeon RX 5600 XT Pulse faster|website=VideoCardz.com|language=en-US|access-date=2020-01-20}}</ref>
| 198 ''252''
| 88 ''112''
| 12,675 ''16,131''
| 6,337 ''8,066''
| 396 ''504''
| 288- 336<ref name="videocardz-powercolor-rx-5600-xt-14gbps">{{Cite web|url=https://videocardz.com/newz/powercolor-also-announces-radeon-rx-5600-xt-with-14-gbps-memory|title=PowerColor also announces Radeon RX 5600 XT with 14 Gbps memory|website=VideoCardz.com|language=en-US|access-date=2020-01-20}}</ref>
| 12000- 14000<ref name="videocardz-powercolor-rx-5600-xt-14gbps"/>
| 150-160 W<ref name="videocardz-powercolor-rx-5600-xt-14gbps"/>
|-
! style="text-align:left;" | Radeon RX 5700<ref name="navi" /><ref>{{cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5700
| title=Radeon RX 5700 Graphics|website=AMD}}</ref><ref name="techpowerup5700">{{Cite web|url=https://www.techpowerup.com/257085/amd-to-slash-radeon-rx-5700-navi-series-prices-ahead-of-launch-usd-399-usd-349|title=AMD to Slash Radeon RX 5700 "Navi" Series Prices Ahead of Launch: $399 & $349|last=Today|first=btarunr|last2=Discuss|first2=07:35|website=TechPowerUp|language=en|access-date=2019-07-05}}</ref><ref name="videocardz5700">{{Cite web|url=https://videocardz.com/newz/amd-to-lower-the-price-of-radeon-rx-5700-series-ahead-of-launch|title=AMD to lower the price of Radeon RX 5700 series ahead of launch|website=VideoCardz.com|language=en-US|access-date=2019-07-05}}</ref><ref>{{Cite web|url=https://www.techpowerup.com/gpu-specs/radeon-rx-5700.c3437|title=AMD Radeon RX 5700 Specs|website=TechPowerUp|language=en|access-date=2019-10-08}}</ref> (Navi 10 XL)
| rowspan=3 | {{dts|2019|07|07|format=mdy}} {{nowrap|$349 USD}} {{nowrap|$399 USD (XT)}} {{nowrap|$449 USD (50th)}}
| 1465 ''1725''
| 211 ''248.4''
| 93.8 ''110.4''
| 13,501 ''15,900''
| 6,751 ''7,949''
| 421.9 ''496.8''
| rowspan=3 | 8
| rowspan=3 | 448
| rowspan=3 | [[GDDR6]] 256-bit
| rowspan=3 | 14000
| 180 W
|-
! style="text-align:left;" | Radeon RX 5700 XT<ref>{{cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5700-xt
| title=Radeon RX 5700 XT Graphics|website=AMD}}</ref><ref name="navi">{{Cite news|url=https://www.pcgamesn.com/amd/amd-radeon-rx-5700-series|title=AMD announces $449 Radeon RX 5700 XT and $379 5700 for July 7 launch|work=PCGamesN|access-date=2019-06-10}}</ref><ref name="techpowerup5700" /><ref name="videocardz5700" /><ref>{{Cite web|url=https://www.techpowerup.com/gpu-specs/radeon-rx-5700-xt.c3339|title=AMD Radeon RX 5700 XT Specs|website=TechPowerUp|language=en|access-date=2019-10-08}}</ref> (Navi 10 XT)
| rowspan=2 | 2560:160:64 40 CU
| 1605 ''1905''
| 256.8 ''304.8''
| 102.7 ''121.9''
| 16,435 ''19,510''
| 8,218 ''9,754''
| 513.6 ''609.6''
| 225 W
|-
! style="text-align:left;" | Radeon RX 5700 XT 50th Anniversary Edition<ref>{{cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5700-xt-50th-anniversary
| title= AMD Radeon RX 5700 XT 50th Anniversary|website=AMD}}</ref><ref>{{Cite news|url=https://www.pcgamesn.com/amd/radeon-rx-5700-xt-release-date-price-specs-performance|title=AMD Radeon RX 5700 XT release date, price, specs, and performance|work=PCGamesN|access-date=2019-06-25}}</ref><ref name="videocardz5700" /><ref>{{Cite web|url=https://www.techpowerup.com/gpu-specs/radeon-rx-5700-xt-50th-anniversary.c3438|title=AMD Radeon RX 5700 XT 50th Anniversary Specs|website=TechPowerUp|language=en|access-date=2019-10-08}}</ref> (Navi 10 XTX)
| 1680 ''1980''
| 268.8 ''316.8''
| 107.5 ''126.7''
| 17,203 ''20,276''
| 8,602 ''10,138''
| 537.6 ''633.6''
| 235 W
|}
{{navbar|AMD Radeon RX 5000|mini=y|plain=y|style=float: right;position: relative;top: -15px;right: 5px;}}
{{notelist|refs=
{{efn|name="boost"|Boost values (if available) are stated below the base value in ''italic''.}}{{efn|name="cconfig"|[[Unified shader model|Unified Shaders]] : [[Texture mapping unit|Texture Mapping Units]] : [[Render output unit|Render Output Units]] and [[Graphics_Core_Next#Compute_units|Compute Units (CU)]]}}
{{efn|name="texture fill"|Texture fillrate is calculated as the number of '''Texture Mapping Units''' multiplied by the base (or boost) core clock speed.}}
{{efn|name="pixel fill"|Pixel fillrate is calculated as the number of '''Render Output Units''' multiplied by the base (or boost) core clock speed.}}
{{efn|name="FLOPS"|Precision performance is calculated from the base (or boost) core clock speed based on a [[Multiply–accumulate operation#Fused multiply–add|FMA]] operation.}}
}}
<noinclude>

{{Template reference list}}
[[Category:Advanced Micro Devices products]]
</noinclude>

Template:AMD Radeon RX 5000

2020-09-05T19:26:37Z

84.250.17.211: Deduplicate VideoCardz RX 5600 XT 14 Gbps reference ("videocardz-powercolor-rx-5600-xt-14gbps")

{| class="wikitable center" style="font-size: 85%;"
! rowspan=2 | Model ([[codename]])
! rowspan=2 | Release Date & Price
! rowspan=2 | [[Microarchitecture|Architecture]] & [[Semiconductor device fabrication|Fab]]
! rowspan=2 | Transistors & Die Size
! colspan=2 | Core
! colspan=2 | [[Fillrate]]{{efn|name="boost"}}{{efn|name="texture fill"}}{{efn|name="pixel fill"}}
! colspan=3 | Processing power{{efn|name="boost"}}{{efn|name="FLOPS"}} ([[Floating-point_operations_per_second|GFLOPS]])
! colspan=4 | Memory
! rowspan=2 | {{abbr|TBP|Typical Board Power}}
! rowspan=2 | Bus interface
|-
! Config{{efn|name="cconfig"}}
! Clock{{efn|name="boost"}} ([[Hertz|MHz]])
! Texture ([[texel (graphics)|GT]]/s)
! Pixel ([[pixel|GP]]/s)
! [[Half-precision floating-point format|Half]]
! [[Single precision floating-point format|Single]]
! [[Double precision floating-point format|Double]]
! Size ([[Gigabyte|GB]])
! Bandwidth (GB/s)
! Bus type & width
! Clock ([[transfer (computing)|MT/s]])
|-
! style="text-align:left;" | Radeon RX 5300<ref>{{Cite web|last=|first=|date=|title=Radeon RX 5300|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5300#product-specs|url-status=live|archive-url=|archive-date=|access-date=|website=}}</ref>

(Navi 14 XL)
|August 28th, 2020
| rowspan="10" |[[RDNA 1|RDNA 1.0]] [[TSMC]] [[7 nanometer|7FF]]
| rowspan="5" |{{val|6.4|e=9}} 158 mm2
| rowspan="5" |1408:88:32 22 CU
|1327
1645
|116.8
144.8
|42.46
52.64
|7,474
9,265
|3,737
4632
|233.5
289.5
|3
|168
|GDDR6
96-bit
|14000
|100 W
| rowspan="5" |[[PCIe 4.0]] ×8 (with x16 connector)<ref>{{Cite web|title=Meet the Sapphire Pulse Radeon RX 5500 XT|url=https://www.anandtech.com/show/15206/the-amd-radeon-rx-5500-xt-review/2|access-date=2019-12-12|website=anandtech.com|language=en-US}}</ref>
|-
! style="text-align:left;" | Radeon RX 5300 XT<ref>{{Cite web|last=|first=|date=|title=Radeon RX 5300 XT 4GB GRDDR5 included with some HP PCs|url=https://support.hp.com/sg-en/document/c06476253|url-status=live|archive-url=|archive-date=|access-date=|website=}}</ref>
(Navi 14 XL)
| rowspan="2" |October 7, 2019<ref>{{Cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5500|title=Radeon RX 5500|last=|first=|date=|website=|url-status=live|archive-url=|archive-date=|access-date=}}</ref>
|1670
1845
|146.7
162.4
|53.44
59.04
|9,405 ''10,390''
|4,703 ''5,196''
|293.9 ''324.7''
| rowspan="3" |4
|112
|GDDR5
128-bit
|14000
|100 W
|-
! style="text-align:left;" | Radeon RX 5500<ref name="videocardz5500">{{Cite web|url=https://videocardz.com/82162/amd-announces-radeon-rx-5500-series-with-gddr6-memory|title=AMD announces Radeon RX 5500 Series with GDDR6 memory|date=2019-10-07|website=VideoCardz.com|language=en-US|access-date=2019-10-07}}</ref> (Navi 14 XT)
| rowspan="1" | 1670 ''1845''
| rowspan="1" | 146.7 ''162.4''
| rowspan="1" | 53.44 ''59.04''
| rowspan="1" | 9,405 ''10,390''
| rowspan="1" | 4,703 ''5,196''
| rowspan="1" | 293.9 ''324.7''
| rowspan="3" | 224
| rowspan="3" |[[GDDR6]] 128-bit
| rowspan="3" | 14000
| rowspan="1" | 150 W<ref>{{Cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5500#product-specs|title=AMD Radeon™ RX 5500 Graphics|website=amd.com|language=en-US|access-date=2019-12-12}}</ref>
|-
! style="text-align:left;" rowspan=2 | Radeon RX 5500 XT<ref>{{Cite web|url=https://videocardz.com/newz/amd-radeon-rx-5500-xt-to-launch-at-169-usd-4gb-and-199-usd-8gb|title=AMD Radeon RX 5500 XT to launch at 169 USD (4GB) and 199 USD (8GB)|website=VideoCardz.com|language=en-US|access-date=2019-12-12}}</ref> (Navi 14 XTX)
| rowspan=2 | December 12, 2019 {{nowrap|$169 USD (4GB)}} {{nowrap|$199 USD (8GB)}}
| rowspan=2 | 1717 ''1845''
| rowspan=2 | 151.1 ''162.4''
| rowspan=2 | 54.94 ''59.04''
| rowspan=2 | 9,670 ''10,390''
| rowspan=2 | 4,835 ''5,196''
| rowspan=2 | 302.2 ''324.7''
| rowspan=2 | 130 W<ref>{{Cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5500-xt#product-specs|title=AMD Radeon™ RX 5500 XT Graphics|website=amd.com|language=en-US|access-date=2019-12-12}}</ref>
|-
| 8
|-
! style="text-align:left;" | Radeon RX 5600<ref>{{Cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5600|title=Radeon RX 5600|last=|first=|date=|website=|url-status=live|archive-url=|archive-date=|access-date=}}</ref> (Navi 10 XE)
| rowspan=2 | January 21, 2020 {{nowrap|$200/$279 USD (XT)}}
| rowspan=5 | {{val|10.3|e=9}} 251 mm2
| 2048:128:64 32 CU
| 1375 ''1560''
| 176 ''199.7''
| 88 ''99.84''
| 11,264 ''12,780''
| 5,632 ''6,390''
| 352 ''399.4''
| rowspan=2 | 6
| 288
| rowspan=2 | [[GDDR6]] 192-bit
| 12000
| 150 W
| rowspan=5 | [[PCIe 4.0]] ×16
|-
! style="text-align:left;" | Radeon RX 5600 XT<ref>{{Cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5600-xt|title=Radeon RX 5600 XT|last=|first=|date=|website=|url-status=live|archive-url=|archive-date=|access-date=}}</ref> (Navi 10 XLE)
| rowspan=2 | 2304:144:64 36 CU
| 1375 ''1750''<ref>{{Cite web|url=https://videocardz.com/newz/sapphire-quietly-makes-radeon-rx-5600-xt-pulse-faster|title=Sapphire quietly makes Radeon RX 5600 XT Pulse faster|website=VideoCardz.com|language=en-US|access-date=2020-01-20}}</ref>
| 198 ''252''
| 88 ''112''
| 12,675 ''16,131''
| 6,337 ''8,066''
| 396 ''504''
| 288- 336<ref name="videocardz-powercolor-rx-5600-xt-14gbps">{{Cite web|url=https://videocardz.com/newz/powercolor-also-announces-radeon-rx-5600-xt-with-14-gbps-memory|title=PowerColor also announces Radeon RX 5600 XT with 14 Gbps memory|website=VideoCardz.com|language=en-US|access-date=2020-01-20}}</ref>
| 12000- 14000<ref name="videocardz-powercolor-5600-14gbps"/>
| 150-160 W<ref name="videocardz-powercolor-5600-14gbps"/>
|-
! style="text-align:left;" | Radeon RX 5700<ref name="navi" /><ref>{{cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5700
| title=Radeon RX 5700 Graphics|website=AMD}}</ref><ref name="techpowerup5700">{{Cite web|url=https://www.techpowerup.com/257085/amd-to-slash-radeon-rx-5700-navi-series-prices-ahead-of-launch-usd-399-usd-349|title=AMD to Slash Radeon RX 5700 "Navi" Series Prices Ahead of Launch: $399 & $349|last=Today|first=btarunr|last2=Discuss|first2=07:35|website=TechPowerUp|language=en|access-date=2019-07-05}}</ref><ref name="videocardz5700">{{Cite web|url=https://videocardz.com/newz/amd-to-lower-the-price-of-radeon-rx-5700-series-ahead-of-launch|title=AMD to lower the price of Radeon RX 5700 series ahead of launch|website=VideoCardz.com|language=en-US|access-date=2019-07-05}}</ref><ref>{{Cite web|url=https://www.techpowerup.com/gpu-specs/radeon-rx-5700.c3437|title=AMD Radeon RX 5700 Specs|website=TechPowerUp|language=en|access-date=2019-10-08}}</ref> (Navi 10 XL)
| rowspan=3 | {{dts|2019|07|07|format=mdy}} {{nowrap|$349 USD}} {{nowrap|$399 USD (XT)}} {{nowrap|$449 USD (50th)}}
| 1465 ''1725''
| 211 ''248.4''
| 93.8 ''110.4''
| 13,501 ''15,900''
| 6,751 ''7,949''
| 421.9 ''496.8''
| rowspan=3 | 8
| rowspan=3 | 448
| rowspan=3 | [[GDDR6]] 256-bit
| rowspan=3 | 14000
| 180 W
|-
! style="text-align:left;" | Radeon RX 5700 XT<ref>{{cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5700-xt
| title=Radeon RX 5700 XT Graphics|website=AMD}}</ref><ref name="navi">{{Cite news|url=https://www.pcgamesn.com/amd/amd-radeon-rx-5700-series|title=AMD announces $449 Radeon RX 5700 XT and $379 5700 for July 7 launch|work=PCGamesN|access-date=2019-06-10}}</ref><ref name="techpowerup5700" /><ref name="videocardz5700" /><ref>{{Cite web|url=https://www.techpowerup.com/gpu-specs/radeon-rx-5700-xt.c3339|title=AMD Radeon RX 5700 XT Specs|website=TechPowerUp|language=en|access-date=2019-10-08}}</ref> (Navi 10 XT)
| rowspan=2 | 2560:160:64 40 CU
| 1605 ''1905''
| 256.8 ''304.8''
| 102.7 ''121.9''
| 16,435 ''19,510''
| 8,218 ''9,754''
| 513.6 ''609.6''
| 225 W
|-
! style="text-align:left;" | Radeon RX 5700 XT 50th Anniversary Edition<ref>{{cite web|url=https://www.amd.com/en/products/graphics/amd-radeon-rx-5700-xt-50th-anniversary
| title= AMD Radeon RX 5700 XT 50th Anniversary|website=AMD}}</ref><ref>{{Cite news|url=https://www.pcgamesn.com/amd/radeon-rx-5700-xt-release-date-price-specs-performance|title=AMD Radeon RX 5700 XT release date, price, specs, and performance|work=PCGamesN|access-date=2019-06-25}}</ref><ref name="videocardz5700" /><ref>{{Cite web|url=https://www.techpowerup.com/gpu-specs/radeon-rx-5700-xt-50th-anniversary.c3438|title=AMD Radeon RX 5700 XT 50th Anniversary Specs|website=TechPowerUp|language=en|access-date=2019-10-08}}</ref> (Navi 10 XTX)
| 1680 ''1980''
| 268.8 ''316.8''
| 107.5 ''126.7''
| 17,203 ''20,276''
| 8,602 ''10,138''
| 537.6 ''633.6''
| 235 W
|}
{{navbar|AMD Radeon RX 5000|mini=y|plain=y|style=float: right;position: relative;top: -15px;right: 5px;}}
{{notelist|refs=
{{efn|name="boost"|Boost values (if available) are stated below the base value in ''italic''.}}{{efn|name="cconfig"|[[Unified shader model|Unified Shaders]] : [[Texture mapping unit|Texture Mapping Units]] : [[Render output unit|Render Output Units]] and [[Graphics_Core_Next#Compute_units|Compute Units (CU)]]}}
{{efn|name="texture fill"|Texture fillrate is calculated as the number of '''Texture Mapping Units''' multiplied by the base (or boost) core clock speed.}}
{{efn|name="pixel fill"|Pixel fillrate is calculated as the number of '''Render Output Units''' multiplied by the base (or boost) core clock speed.}}
{{efn|name="FLOPS"|Precision performance is calculated from the base (or boost) core clock speed based on a [[Multiply–accumulate operation#Fused multiply–add|FMA]] operation.}}
}}
<noinclude>

{{Template reference list}}
[[Category:Advanced Micro Devices products]]
</noinclude>

Template:Failed verification/doc

2020-08-11T01:59:13Z

84.250.17.211: /* Redirects */ Add Template:Not in refs (per TfD merge)

{{Documentation subpage}}

{{tsh|fv}}

The {{tl|Failed verification}} tag will categorise tagged articles into [[:Category:All articles with failed verification]]. This [[Help:Template|template]] is a [[Wikipedia:Avoid self-references|self-reference]] and thus is part of the Wikipedia project rather than the encyclopedic content.

== When to use ==
Use this tag '''only if''':

# an [[Wikipedia:Inline citation|inline citation]] to a source is given,
# you have checked the source,
# the source does not support what is contained in the article, '''and'''
# despite the source not supporting the article, the source still contains useful information on the topic.

For example, if the article says that 26% of statistics are made up, and the source says that statistics are made up without giving a percentage, then that information has failed verification. If you are unable to fix the error, then you should tag the information as not matching the named source. If the discrepancy between the source and the article isn't obvious, then please explain the situation in detail on the talk page.

If the source given is an unreachable website, keep the source and mark it with {{Tlx|Dead link}} instead. See [[Wikipedia:Link rot]] and [[WP:DEADREF]] for more information.

If no source is given, and you believe that [[WP:MINREF|an inline citation is necessary]] for that information, then use {{tlx|Citation needed}}.

If the source has absolutely no relevance to any part of the article, delete the reference and replace with {{tlx|Citation needed}}.

== How to use ==
===Placement===

The template should be placed outside the reference (<code><nowiki><ref> ... </ref></nowiki></code>), within the article's text:
:... 26% of statistics are made up.<code><nowiki><ref>some alleged source for this</ref>{{Failed verification|date=</nowiki>{{CURRENTMONTHNAME}} {{CURRENTYEAR}}}}</code> Next sentence in the article.

===Common form (with current date)===

<code>{{Failed verification|date={{CURRENTMONTHNAME}} {{CURRENTYEAR}}}}</code>

===Optional parameters===

Link to the relevant section on the current page's talk page with:

:<code>|talk={{var|Section title}}</code>

or to a discussion elsewhere with:

:<code>|talkpage={{var|Talk:Page name}}</code>

or:

:<code>|talkpage={{var|Talk:Page name}}#{{var|Section title}}</code>

Add a {{em|brief}} note on the nature of the verification failure with:

:<code>|reason={{var|A sentence here.}}</code>

This is displayed as a mouse-over tooltip, and may be of use to later editors trying to resolve the verification issue. It {{strong|must not}} contain any markup, like italics, links, etc., and any use of the double-quote character (<samp>"</samp>) must be escaped, e.g. as <code>&quot;</code> – otherwise the tooltip will break. This is a limitation of HTML, not of the template.

== Template data ==

{{TemplateDataHeader}}
<templatedata>
{
"description": "The template will categorize articles into [[:Category:All articles with failed verification]].",
"params": {
"date": {
"label": "Month and year",
"description": "Provides the month and year (e.g. 'January 2013', but not 'jan13').",
"type": "string",
"autovalue": "{{subst:CURRENTMONTHNAME}} {{subst:CURRENTYEAR}}",
"suggested": true
},
"talk": {
"label": "Current page's relevant talk section",
"description": "Title of the appropriate section of the current page's talk page, for further discussion of the verification failure (e.g. 'Section title').",
"type": "string"
},
"talkpage": {
"label": "Another page's relevant talk section",
"description": "Title of the appropriate section of another page's talk page, for further discussion of the verification failure (e.g. 'Talk:Page name#Section title').",
"type": "string"
},
"reason": {
"label": "Reason",
"description": "A brief note, displayed as a mouse-over tooltip. May be of use to later editors.",
"type": "string"
}
}
}
</templatedata>

==Redirects==
#{{Tl|Badref}}
#{{Tl|Failed ref}}
#{{Tl|Failed reference}}
#{{Tl|Failedverification}}
#{{Tl|Fails verification}}
#{{Tl|FV}}
#{{Tl|Fv}}
#{{Tl|Ncg}}
#{{Tl|Nicg}}
#{{Tl|Not in citation}}
#{{Tl|Not in citation given}}
#{{Tl|Not in ref}}
#{{Tl|Not in refs}}
#{{Tl|Not in reference}}
#{{Tl|Not in source}}
#{{Tl|Not in source given}}
#{{Tl|Not specifically in source}}
#{{Tl|Notincitation}}
#{{Tl|Notincitationgiven}}
#{{Tl|Notinref}}
#{{Tl|Notinsource}}
#{{Tl|Notinsourcegiven}}
#{{Tl|Verification failed}}
#{{Tl|Verification-failed}}

==See also==
*{{tlx|Failed verification span}}: Use when inline citations have been supplied which support some portion of the statement in question, but not all of it.
*{{tlx|Text-source inline}}: Use when multiple inline citations to a source are given, but not all of them support the same information.
*{{tlx|Unreliable source?}}: Use when an inline citation to a source is given, but it is questionable whether the source used is reliable for supporting the statement.
*{{tlx|Unreliable source?|certain{{=}}y}}: Use when an inline citation to a source is given, but it is an unreliable source.
*{{Tlx|Cite check}}: Use when the article or section may have inappropriate or misinterpreted citations (generates a hatnote).
*{{tlx|Verify source}}
* [[Wikipedia:Citing sources]], especially [[Wikipedia:Citing sources#Unsourced material|Unsourced material]]
* [[Wikipedia:Identifying reliable sources]]
* [[Wikipedia:Template messages/Cleanup#Verifiability and sources]]
* [[Wikipedia:Template messages/Sources of articles]]
* [[Wikipedia:Verifiability]]
* [[Wikipedia:WikiProject Fact and Reference Check]]

{{Inline tags}}

<includeonly>{{Sandbox other||

[[Category:Inline citation and verifiability dispute templates]]

}}</includeonly>

Template:Current event inline/doc

2020-07-15T22:49:43Z

84.250.17.211: Add Template:Inline tags

{{Documentation subpage}}


== Usage ==

{{Tlx|Current event inline}} creates {{Current event inline}}.

{{Tlx|Current event inline|date{{=}}{{Currentmonthname}} {{Currentyear}}}} creates {{Current event inline|date={{Currentmonthname}} {{Currentyear}}}}.

{{Tlx|Current event inline|date{{=}}{{Currentmonthname}} {{Currentyear}}|hide{{=}}y}} creates {{Current event inline|date={{Currentmonthname}} {{Currentyear}}|hide=y}}.

== Parameters ==
* {{Para|date}}: the date the tag was added. This gets added to the template text, after "as of".
* {{Para|hide}}: enter any text in this parameter to hide the date from the template text. For use in conjunction with "date".

== TemplateData ==
{{TemplateData header}}
<templatedata>
{
"description": "Use this inline template indicate that a statement may be outdated and in need of updating.",
"format": "inline",
"params": {
"date": {
"label": "Month and year",
"description": "Month and year of tagging; e.g., 'January 2013', but not 'jan13'. Adds this to the template text, after 'as of'.",
"type": "string",
"autovalue": "{{subst:CURRENTMONTHNAME}} {{subst:CURRENTYEAR}}",
"example": "January 2013",
"suggested": true
},
"hide": {
"label": "Hide date from text",
"description": "Enter any text in this parameter to hide the date from the template text. For use in conjunction with 'date'.",
"type": "string",
"example": "y",
"suggested": true
}
},
"paramOrder": [
"date",
"hide"
]
}
</templatedata>


{{Inline tags}}

<includeonly>{{Sandbox other||

[[Category:Inline cleanup templates]]
[[Category:Time and date maintenance templates]]
}}</includeonly>

Template:Exchange-rate regime for EU members

2020-07-13T13:25:40Z

84.250.17.211: Fix a typo: "Finish" → "Finnish"

<center>
<timeline>
DateFormat = dd/mm/yyyy
ImageSize = width:900 height:auto barincrement:25
PlotArea = left:80 right:40 bottom:30 top:50
TextData =
pos:(250,750)
fontsize:XL
textcolor:black
text:"Exchange-rate regimes for EU members"

Colors =
id:eu value:rgb(1,0.65,0) legend:EU_members_outside_ERM_with_a_floating_currency_(free_float_or_crawling_peg)
id:eupeg value:rgb(0,0.5,0) legend:EU_members_outside_ERM_with_a_currency_pegged_to_D-Mark/ECU/euro
id:erm value:rgb(0.64,0.76,0.85) legend:EU_members_with_currency_pegged_to_the_ECU/euro_via_the_ERM
id:euroland value:rgb(0.2,0.4,1) legend:EU_members_with_the_euro_as_their_currency
id:line value:gray(0.8)

Period = from:01/01/1979 till:31/12/2020
TimeAxis = orientation:horizontal format:yyyy
ScaleMajor = unit:year increment:2 start:1979 gridcolor:line
AlignBars = justify
Legend = left:95 top:100

BarData =
bar:Belgium
bar:France
bar:Germany
bar:Ireland
bar:Italy
bar:Luxembourg
bar:Netherlands
bar:Denmark
bar:United_Kingdom
bar:Greece
bar:Spain
bar:Portugal
bar:Austria
bar:Finland
bar:Sweden
bar:Slovenia
bar:Cyprus
bar:Malta
bar:Slovakia
bar:Estonia
bar:Latvia
bar:Lithuania
bar:Hungary
bar:Poland
bar:Czech_Republic
bar:Bulgaria
bar:Romania
bar:Croatia

PlotData =
width:18 fontsize:S textcolor:black anchor:from align:right

bar:Belgium color:erm from:13/03/1979 till:31/12/1998 shift:(-3,-5) text:Belgium
color:euroland from:01/01/1999 till:31/12/2020
bar:France color:erm from:13/03/1979 till:31/12/1998 shift:(-3,-5) text:France
color:euroland from:01/01/1999 till:31/12/2020
bar:Germany color:erm from:13/03/1979 till:31/12/1998 shift:(-3,-5) text:Germany
color:euroland from:01/01/1999 till:31/12/2020
bar:Ireland color:erm from:13/03/1979 till:31/12/1998 shift:(-3,-5) text:Ireland
color:euroland from:01/01/1999 till:31/12/2020
bar:Italy color:erm from:13/03/1979 till:16/09/1992 shift:(-3,-5) text:Italy
color:eu from:17/09/1992 till:24/11/1996
color:erm from:25/11/1996 till:31/12/1998
color:euroland from:01/01/1999 till:31/12/2020
bar:Luxembourg color:erm from:13/03/1979 till:31/12/1998 shift:(-3,-5) text:Luxembourg
color:euroland from:01/01/1999 till:31/12/2020
bar:Netherlands color:erm from:13/03/1979 till:31/12/1998 shift:(-3,-5) text:Netherlands
color:euroland from:01/01/1999 till:31/12/2020
bar:Denmark color:erm from:13/03/1979 till:31/12/2020 shift:(-3,-5) text:Denmark
bar:United_Kingdom color:eu from:13/03/1979 till:28/02/1987 shift:(-3,-5) text:United_Kingdom
color:eupeg from:01/03/1987 till:09/03/1988
color:eu from:10/03/1988 till:07/10/1990
color:erm from:08/10/1990 till:15/09/1992
color:eu from:16/09/1992 till:31/01/2019
bar:Greece color:eu from:01/01/1981 till:31/12/1995 shift:(-3,-5) text:Greece
color:eupeg from:01/01/1996 till:13/03/1998
color:erm from:14/03/1998 till:31/12/2000
color:euroland from:01/01/2001 till:31/12/2020
bar:Spain color:eupeg from:01/01/1986 till:18/06/1989 shift:(-3,-5) text:Spain
color:erm from:19/06/1989 till:31/12/1998
color:euroland from:01/01/1999 till:31/12/2020
bar:Portugal color:eu from:01/01/1986 till:30/09/1990 shift:(-3,-5) text:Portugal
color:eupeg from:01/10/1990 till:05/04/1992
color:erm from:06/04/1992 till:31/12/1998
color:euroland from:01/01/1999 till:31/12/2020
bar:Austria color:eupeg from:01/01/1995 till:08/01/1995 shift:(-3,-5) text:Austria
color:erm from:09/01/1995 till:31/12/1998
color:euroland from:01/01/1999 till:31/12/2020
bar:Finland color:eu from:01/01/1995 till:13/10/1996 shift:(-3,-5) text:Finland
color:erm from:14/10/1996 till:31/12/1998
color:euroland from:01/01/1999 till:31/12/2020
bar:Sweden color:eu from:01/01/1995 till:31/12/2020 shift:(-3,-5) text:Sweden
bar:Slovenia color:eu from:01/05/2004 till:27/06/2004 shift:(-3,-5) text:Slovenia
color:erm from:28/06/2004 till:31/12/2006
color:euroland from:01/01/2007 till:31/12/2020
bar:Cyprus color:eupeg from:01/05/2004 till:01/05/2005 shift:(-3,-5) text:Cyprus
color:erm from:02/05/2005 till:31/12/2007
color:euroland from:01/01/2008 till:31/12/2020
bar:Malta color:eupeg from:01/05/2004 till:01/05/2005 shift:(-3,-5) text:Malta
color:erm from:02/05/2005 till:31/12/2007
color:euroland from:01/01/2008 till:31/12/2020
bar:Slovakia color:eu from:01/05/2004 till:27/11/2005 shift:(-3,-5) text:Slovakia
color:erm from:28/11/2005 till:31/12/2008
color:euroland from:01/01/2009 till:31/12/2020
bar:Estonia color:eupeg from:01/05/2004 till:27/06/2004 shift:(-3,-5) text:Estonia
color:erm from:28/06/2004 till:31/12/2010
color:euroland from:01/01/2011 till:31/12/2020
bar:Latvia color:eu from:01/05/2004 till:31/12/2004 shift:(-3,-5) text:Latvia
color:eupeg from:01/01/2005 till:01/05/2005
color:erm from:02/05/2005 till:31/12/2013
color:euroland from:01/01/2014 till:31/12/2020
bar:Lithuania color:eupeg from:01/05/2004 till:27/06/2004 shift:(-3,-5) text:Lithuania
color:erm from:28/06/2004 till:31/12/2014
color:euroland from:01/01/2015 till:31/12/2020
bar:Hungary color:eupeg from:01/05/2004 till:25/02/2008 shift:(-3,-5) text:Hungary
color:eu from:26/02/2008 till:31/12/2020
bar:Poland color:eu from:01/05/2004 till:31/12/2020 shift:(-3,-5) text:Poland
bar:Czech_Republic color:eu from:01/05/2004 till:31/12/2020 shift:(-3,-5) text:Czech_Republic
bar:Bulgaria color:eupeg from:01/01/2007 till:31/12/2020 shift:(-3,-5) text:Bulgaria
color:erm from:10/07/2020 till:31/12/2020
bar:Romania color:eu from:01/01/2007 till:31/12/2020 shift:(-3,-5) text:Romania
bar:Croatia color:eu from:01/07/2013 till:31/12/2020 shift:(-3,-5) text:Croatia
color:erm from:10/07/2020 till:31/12/2020
</timeline>

'''Sources:''' ''[http://ec.europa.eu/economy_finance/publications/european_economy/convergence_reports_en.htm EC convergence reports 1996-2014], [https://www.bancaditalia.it/pubblicazioni/pubsto/quaristo/qrs10/Q10_Garofalo.pdf Italian lira] {{dead link|date=November 2017}}, [http://www.hec.unil.ch/pbacchetta/Printed%20papers/WE97.pdf Spanish peseta], [http://www.imf.org/external/pubs/ft/wp/wp9775.pdf Portuguese escudo], [http://www2.wu-wien.ac.at/ecsa//emu/papgenberg.pdf Finnish markka], [http://www.imf.org/external/pubs/ft/wp/wp9775.pdf Greek drachma], [https://libcom.org/library/britain-european-exchange-rate-mechanism UK pound]''
</center>

Template:Ia-focus

2020-04-08T03:05:31Z

84.250.17.211: Move Template:Twinkle standard installation inside Template:Documentation

{{imbox
| type = style
| name = Ia-focus
| text = '''The main subject of this image is blurry and out of [[Focus (optics)|focus]].''' Unless this is intentional, please replace the image with one that is clearly in focus.
| below =''To image reviewers and patrollers:'' If you disagree with this assessment please leave a comment on the talk page.
}}<noinclude>
{{Documentation
| content = {{Missing documentation|date=April 2020}}
{{Twinkle standard installation}}
}}
[[Category:Image quality templates|{{PAGENAME}}]]
</noinclude>

Template:Ia-focus

2020-04-08T03:04:34Z

84.250.17.211: Add a missing space character after Template:Documentation's "content" parameter

{{imbox
| type = style
| name = Ia-focus
| text = '''The main subject of this image is blurry and out of [[Focus (optics)|focus]].''' Unless this is intentional, please replace the image with one that is clearly in focus.
| below =''To image reviewers and patrollers:'' If you disagree with this assessment please leave a comment on the talk page.
}}<noinclude>
{{Documentation
| content = {{Missing documentation|date=April 2020}}
}}
{{Twinkle standard installation}}
[[Category:Image quality templates|{{PAGENAME}}]]
</noinclude>

Template:Ia-focus

2020-04-08T03:03:40Z

84.250.17.211: Add Template:Documentation with Template:Missing documentation, date=April 2020

{{imbox
| type = style
| name = Ia-focus
| text = '''The main subject of this image is blurry and out of [[Focus (optics)|focus]].''' Unless this is intentional, please replace the image with one that is clearly in focus.
| below =''To image reviewers and patrollers:'' If you disagree with this assessment please leave a comment on the talk page.
}}<noinclude>
{{Documentation
| content= {{Missing documentation|date=April 2020}}
}}
{{Twinkle standard installation}}
[[Category:Image quality templates|{{PAGENAME}}]]
</noinclude>

Template:Estrogen dosages for menopausal hormone therapy

2019-03-29T16:46:45Z

84.250.17.211: Add inline Template:Documentation; wrap "see also" and "references" sections into it

{| class="wikitable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="text-align:left; margin-left:auto; margin-right:auto; border:none;"
|+ class="nowrap" | {{Navbar|Estrogen dosages for menopausal hormone therapy|mini=y}} <noinclude>[[Estrogen (medication)|Estrogen]]</noinclude><includeonly>Estrogen</includeonly> dosages for <noinclude>[[menopausal hormone therapy]]</noinclude><includeonly>menopausal hormone therapy</includeonly>
|-
! Route/form !! Estrogen !! Low !! Standard !! High
|-
| rowspan="8" | [[Oral administration|Oral]] || {{No selflink|Estradiol (medication)|Estradiol}} || 0.5–1 mg/day || 1–2 mg/day || 2–4 mg/day
|-
| {{No selflink|Estradiol valerate}} || 0.5–1 mg/day || 1–2 mg/day || 2–4 mg/day
|-
| {{No selflink|Estradiol acetate}} || 0.45–0.9 mg/day || 0.9–1.8 mg/day || 1.8–3.6 mg/day
|-
| {{No selflink|Conjugated estrogens}} || 0.3–0.45 mg/day || 0.625 mg/day || 0.9–1.25 mg/day
|-
| {{No selflink|Esterified estrogens}} || 0.3–0.45 mg/day || 0.625 mg/day || 0.9–1.25 mg/day
|-
| {{No selflink|Estropipate}} || 0.75 mg/day || 1.5 mg/day || 3 mg/day
|-
| {{No selflink|Estriol (medication)|Estriol}} || 1–2 mg/day || 2–4 mg/day || 4–8 mg/day
|-
| {{No selflink|Ethinylestradiol}}a || – || 5 μg/day || –
|-
| [[Nasal spray]] || {{No selflink|Estradiol (medication)|Estradiol}} || 150 μg/day || 300 μg/day || –
|-
| [[Transdermal patch]] || {{No selflink|Estradiol (medication)|Estradiol}} || 25 μg/dayb || 50 μg/dayb || 100 μg/dayb
|-
| [[Transdermal gel]] || {{No selflink|Estradiol (medication)|Estradiol}} || 0.5 mg/day || 1–1.5 mg/day || 2–3 mg/day
|-
| rowspan="2" | [[Vaginal administration|Vaginal]] || {{No selflink|Estradiol (medication)|Estradiol}} || 25 μg/day || – || –
|-
| {{No selflink|Estriol (medication)|Estriol}} || 30 μg/day || 0.5 mg 2x/week || 0.5 mg/day
|-
| rowspan="3" | {{abbrlink|IM|Intramuscular}} or [[subcutaneous injection|{{abbr|SC|subcutaneous}} injection]] || {{No selflink|Estradiol valerate}} || – || – || 4 mg 1x/4 weeks
|-
| {{No selflink|Estradiol cypionate}} || 1 mg 1x/3–4 weeks || 3 mg 1x/3–4 weeks || 5 mg 1x/3–4 weeks
|-
| {{No selflink|Estradiol benzoate}} || 0.5 mg 1x/week || 1 mg 1x/week || 1.5 mg 1x/week
|-
| [[Subcutaneous implant|{{abbr|SC|Subcutaneous}} implant]] || {{No selflink|Estradiol (medication)|Estradiol}} || 25 mg 1x/6 months || 50 mg 1x/6 months || 100 mg 1x/6 months
|- class="sortbottom"
| colspan="8" style="width: 1px;" | '''Footnotes:''' a = No longer used or recommended, due to health concerns. b = As a single patch applied once or twice per week (worn for 3–4 days or 7 days), depending on the formulation. '''Note:''' Dosages are not necessarily equivalent. '''Sources:''' <ref name="pmid16112947">{{cite journal | vauthors = Kuhl H | title = Pharmacology of estrogens and progestogens: influence of different routes of administration | journal = Climacteric | volume = 8 Suppl 1 | issue = | pages = 3–63 | year = 2005 | pmid = 16112947 | doi = 10.1080/13697130500148875 | url = http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf}}</ref><ref name="KuhlWiegratz2008">{{cite book|last1=Kuhl|first1=Herbert|last2=Wiegratz|first2=Inka|title=Klimakterium, Postmenopause und Hormonsubstitution|trans-title=Climacteric, Postmenopause and Hormone Replacement|edition=4|url=https://www.amazon.de/Klimakterium-Postmenopause-Hormonsubstitution-Herbert-Kuhl/dp/3837420434/|date=1 January 2008|language=German|publisher=UNI-MED-Verlag|isbn=978-3-83742-043-2|page=188}}</ref><ref name="pmid18365854">{{cite journal | vauthors = Birkhäuser MH, Panay N, Archer DF, Barlow D, Burger H, Gambacciani M, Goldstein S, Pinkerton JA, Sturdee DW | title = Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause | journal = Climacteric | volume = 11 | issue = 2 | pages = 108–23 | date = April 2008 | pmid = 18365854 | doi = 10.1080/13697130801983921 | url = }}</ref><ref name="Borgelt2010_">{{cite book|author=Laura Marie Borgelt|title=Women's Health Across the Lifespan: A Pharmacotherapeutic Approach|url=https://books.google.com/books?id=riP3pxq2jWAC&pg=PA257|year=2010|publisher=ASHP|isbn=978-1-58528-194-7|pages=257–}}</ref><ref name="DiPiroTalbert2017_">{{cite book|vauthors= DiPiro JT, Talbert RL, Yee GC,Matzke GR, Wells BG, Posey LM|title=Pharmacotherapy: A Pathophysiologic Approach, Tenth Edition|url=https://books.google.com/books?id=BwF9DQAAQBAJ|date=23 January 2017|publisher=McGraw-Hill Education|isbn=978-1-259-58749-8|page=1295}}</ref><ref name="pmid18042008">{{cite journal | vauthors = Simon JA, Snabes MC | title = Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen | journal = Expert Opin Investig Drugs | volume = 16 | issue = 12 | pages = 2005–20 | date = December 2007 | pmid = 18042008 | doi = 10.1517/13543784.16.12.2005 | url = }}</ref><ref name="FritzSperoff2012_Composition">{{cite book|author1=Marc A. Fritz|author2=Leon Speroff|title=Clinical Gynecologic Endocrinology and Infertility|url=https://books.google.com/books?id=KZLubBxJEwEC&pg=PA751|date=28 March 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-4511-4847-3|pages=751–753}}</ref><ref name="ThomasKeenan1986_">{{cite book|last1=Thomas|first1=John A.|last2=Keenan|first2=Edward J.|chapter=Estrogens and Antiestrogenic Drugs|pages=135–165|doi=10.1007/978-1-4684-5036-1_7|title=Principles of Endocrine Pharmacology|url=https://books.google.com/books?id=mTagBQAAQBAJ&pg=PA150|date=6 December 1986|publisher=Springer Science & Business Media|isbn=978-1-4684-5036-1}}</ref><ref name="Depo-Estradiol-Label 2005">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/085470s015lbl.pdf]</ref>
|}<noinclude>{{Documentation|content=
==See also==
* [[Template:Estrogen dosages for breast and prostate cancer]]
* [[Template:Medications and dosages used in hormone therapy for transgender women]]

==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Estrogen dosages for prostate cancer

2019-03-29T16:44:44Z

84.250.17.211: Add inline Template:Documentation; wrap references into it

{{ref info}}

{| class="wikitable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="text-align:left; margin-left:auto; margin-right:auto; border:none;"
|+ class="nowrap" | {{Navbar|Estrogen dosages for breast and prostate cancer|mini=y}} <noinclude>[[Estrogen (medication)|Estrogen]]</noinclude><includeonly>Estrogen</includeonly> dosages for <noinclude>[[breast cancer|breast]]</noinclude><includeonly>breast</includeonly> and <noinclude>[[prostate cancer]]</noinclude><includeonly>prostate cancer</includeonly>
|-
! Route/form !! Estrogen !! Cancer !! Dosage !! Ref(s)
|-
| rowspan="11" | [[Oral administration|Oral]] || {{No selflink|Estradiol (medication)|Estradiol}} || Breast || 6–30 mg/day || <ref name="pmid27889048">{{cite journal | vauthors = Coelingh Bennink HJ, Verhoeven C, Dutman AE, Thijssen J | title = The use of high-dose estrogens for the treatment of breast cancer | journal = Maturitas | volume = 95 | issue = | pages = 11–23 | date = January 2017 | pmid = 27889048 | doi = 10.1016/j.maturitas.2016.10.010 | url = }}</ref>
|-
| rowspan="2" | {{No selflink|Conjugated estrogens}} || Breast || 10 mg 3x/day || <ref name="ThomasKeenan1986_">{{cite book|last1=Thomas|first1=John A.|last2=Keenan|first2=Edward J.|chapter=Estrogens and Antiestrogenic Drugs|pages=135–165|doi=10.1007/978-1-4684-5036-1_7|title=Principles of Endocrine Pharmacology|url=https://books.google.com/books?id=mTagBQAAQBAJ&pg=PA150|date=6 December 1986|publisher=Springer Science & Business Media|isbn=978-1-4684-5036-1}}</ref>
|-
| Prostate || 1.25–2.5 mg 3x/day || <ref name="ThomasKeenan1986_" /><ref name="Oettel1999_">{{cite book|last1=Oettel|first1=M|chapter=Estrogens and Antiestrogens in the Male|pages=505–571|doi=10.1007/978-3-642-60107-1_25|editor1=Michael Oettel|editor2=Ekkehard Schillinger|title=Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen|url=https://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA538|date=1999|publisher=Springer Science & Business Media|isbn=978-3-642-60107-1|issn=0171-2004}}</ref>
|-
| rowspan="2" | {{No selflink|Ethinylestradiol}} || Breast || 1–3 mg/day || <ref name="ThomasKeenan1986_" /><ref name="pmid27889048" />
|-
| Prostate || 0.15–2 mg/day || <ref name="ThomasKeenan1986_" /><ref name="Oettel1999_" />
|-
| {{No selflink|Ethinylestradiol sulfonate}} || Prostate || 1–2 mg 1x/week || <ref name="HöflingHeynemann2014">{{cite journal|last1=Höfling|first1=G.|last2=Heynemann|first2=H.|title=Die orale Östrogentherapie des fortgeschrittenen Prostatakarzinoms — Anlaß für eine Neubewertung?|trans-title=Oral Estrogen Therapy for Advanced Prostate Cancer — Reason for Revaluation?|journal=Der Urologe B|volume=38|issue=2|year=2014|pages=165–170|issn=0042-1111|doi=10.1007/s001310050185}}</ref><ref name="Oettel1999_" />
|-
| rowspan="2" | {{No selflink|Diethylstilbestrol}} || Breast || 5 mg 3x/day || <ref name="ThomasKeenan1986_" />
|-
| Prostate || 1–3 mg/day || <ref name="ThomasKeenan1986_" />
|-
| {{No selflink|Fosfestrol}} || Prostate || 120–480 mg 1–3x/day || <ref name="Martindale-Fosfestrol">{{cite book |editor=Sweetman, Sean C. |chapter=Sex hormones and their modulators |title=Martindale: The Complete Drug Reference |edition=36th |year=2009 |page=2104–2105 |publisher=Pharmaceutical Press |location=London|isbn=978-0-85369-840-1|url=https://www.medicinescomplete.com/mc/martindale/}}</ref><ref name="BruchhausenDannhardt2013_">{{cite book |author=Franz von Bruchhausen|author2=Gerd Dannhardt|author3=Siegfried Ebel|author4=August W. Frahm |author5=Eberhard Hackenthal |author6=Ulrike Holzgrabe |title=Hagers Handbuch der Pharmazeutischen Praxis: Band 8: Stoffe E-O|url=https://books.google.com/books?id=8vSjBgAAQBAJ&pg=PA301|date=2 July 2013|publisher=Springer-Verlag|isbn=978-3-642-57994-3|pages=301–}}</ref>
|-
| {{No selflink|Chlorotrianisene}} || Prostate || 12–25 mg/day || <ref name="ThomasKeenan1986_" />
|-
| {{No selflink|Estramustine phosphate}} || Prostate || 140–1400 mg/day || <ref name="pmid7579781">{{cite journal | vauthors = Perry CM, McTavish D | title = Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer | journal = Drugs Aging | volume = 7 | issue = 1 | pages = 49–74 | date = July 1995 | pmid = 7579781 | doi = 10.2165/00002512-199507010-00006 | url = }}</ref>
|-
| [[Transdermal patch]] || {{No selflink|Estradiol (medication)|Estradiol}} || Prostate || 2–6x 100 μg/day || <ref name="pmid17019433">{{cite journal | vauthors = Ockrim J, Lalani EN, Abel P | title = Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy | journal = Nat Clin Pract Oncol | volume = 3 | issue = 10 | pages = 552–63 | date = October 2006 | pmid = 17019433 | doi = 10.1038/ncponc0602 | url = }}</ref><ref name="pmid12686820">{{cite journal | vauthors = Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD | title = Transdermal estradiol therapy for advanced prostate cancer--forward to the past? | journal = J. Urol. | volume = 169 | issue = 5 | pages = 1735–7 | date = May 2003 | pmid = 12686820 | doi = 10.1097/01.ju.0000061024.75334.40 | url = }}</ref>
|-
| rowspan="7" | {{abbrlink|IM|Intramuscular}} or [[subcutaneous injection|{{abbr|SC|subcutaneous}} injection]] || {{No selflink|Estradiol benzoate}} || Prostate || 1.66 mg 3x/week || <ref name="NNR1949_" />
|-
| {{No selflink|Estradiol dipropionate}} || Prostate || 5 mg/1x week || <ref name="NNR1949_">{{cite journal|title=NNR: Products Recently Accepted by the A. M. A. Council on Pharmacy and Chemistry|journal=Journal of the American Pharmaceutical Association (Practical Pharmacy ed.)|volume=10|issue=11|year=1949|pages=692–694|issn=00959561|doi=10.1016/S0095-9561(16)31995-8}}</ref>
|-
| {{No selflink|Estradiol valerate}} || Prostate || 30 mg 1x/1–2 weeks || <ref name="Delestrogen-Label_">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009402s052lbl.pdf</ref>
|-
| {{No selflink|Estradiol undecylate}} || Prostate || 100 mg/4 weeks || <ref name="pmid18268497" />
|-
| rowspan="2" | {{No selflink|Polyestradiol phosphate}} || Breast || 40–80 mg 1x/4 weeks || <ref name="Pharmanovia">http://pharmanovia.com/product/estradurin/</ref>
|-
| Prostate || 160–320 mg/1x 4 weeks || <ref name="Pharmanovia" /><ref name="pmid18268497">{{cite journal | vauthors = Norman G, Dean ME, Langley RE, Hodges ZC, Ritchie G, Parmar MK, Sydes MR, Abel P, Eastwood AJ | title = Parenteral oestrogen in the treatment of prostate cancer: a systematic review | journal = Br. J. Cancer | volume = 98 | issue = 4 | pages = 697–707 | date = February 2008 | pmid = 18268497 | pmc = 2259178 | doi = 10.1038/sj.bjc.6604230 | url = }}</ref>
|-
| {{No selflink|Estrone (medication)|Estrone}} || Prostate || 2–4 mg 2–3x/week || <ref name="ThomasKeenan1986_" />
|-
| rowspan="2" | [[Intravenous injection|{{abbr|IV|Intravenous}} injection]] || {{No selflink|Fosfestrol}} || Prostate || 300–1200 mg 1–7x/week || <ref name="Martindale-Fosfestrol" /><ref name="BruchhausenDannhardt2013_" />
|-
| {{No selflink|Estramustine phosphate}} || Prostate || 240–450 mg/day || <ref name="pmid7579781" /><ref name="pmid9515186">{{cite journal | vauthors = Bergenheim AT, Henriksson R | title = Pharmacokinetics and pharmacodynamics of estramustine phosphate | journal = Clin Pharmacokinet | volume = 34 | issue = 2 | pages = 163–72 | date = February 1998 | pmid = 9515186 | doi = 10.2165/00003088-199834020-00004 | url = }}</ref>
|-
! colspan="5" style="width: 1px;" | '''Note:''' Dosages are not necessarily equivalent.
|}<noinclude>{{Documentation|content=
==See also==
* [[Template:Estrogen dosages for menopausal hormone therapy]]
* [[Template:Medications and dosages used in hormone therapy for transgender women]]

==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Endogenous estradiol production rates and plasma estrogen levels

2019-03-27T12:58:17Z

84.250.17.211: Remove inline styling from table: Prone to not displaying well on low width resolution displays, especially with margins.

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
|+ class="nowrap" | {{Navbar|Endogenous estradiol production rates and plasma estrogen levels|mini=y}} Endogenous <noinclude>[[estradiol (medication)|estradiol]]</noinclude><includeonly>estradiol</includeonly> production rates and plasma <noinclude>[[estrogen (medication)|estrogen]]</noinclude><includeonly>estrogen</includeonly> levels
|-
! Group !! {{abbr|E2|Estradiol}} ({{abbr|prod|production rate}}) !! {{abbr|E2|Estradiol}} (levels) !! {{abbr|E1|Estrone}} (levels) !! {{abbr|Ratio|Ratio (E2:E1)}}
|-
| [[Puberty|Pubertal]] girls   [[Tanner scale#Definitions of stages|Tanner stage I]] (childhood)   [[Tanner scale#Definitions of stages|Tanner stage II]] (ages 8–12)   [[Tanner scale#Definitions of stages|Tanner stage III]] (ages 10–13)   [[Tanner scale#Definitions of stages|Tanner stage IV]] (ages 11–14)   [[Tanner scale#Definitions of stages|Tanner stage V]] (ages 12–15)     [[Follicular phase|Follicular]] (days 1–14)     [[Luteal phase|Luteal]] (days 15–28) ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}   {{abbr|ND|No data}} {{abbr|ND|No data}} ||   9 (<9–20) pg/mL 15 (<9–30) pg/mL 27 (<9–60) pg/mL 55 (16–85) pg/mL   50 (30–100) pg/mL 130 (70–300) pg/mL ||   13 (<9–23) pg/mL 18 (10–37) pg/mL 26 (17–58) pg/mL 36 (23–69) pg/mL   44 (30–89) pg/mL 75 (39–160) pg/mL ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}   {{abbr|ND|No data}} {{abbr|ND|No data}}
|-
| [[Prepuberty|Prepubertal]] boys || {{abbr|ND|No data}} || 2–8 pg/mL || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[Premenopause|Premenopausal]] women   [[Follicular phase|Early follicular phase]] (days 1–4)   [[Follicular phase|Mid follicular phase]] (days 5–9)   [[Follicular phase|Late follicular phase]] (days 10–14)   [[Luteal phase]] (days 15–28)   [[Oral contraceptive]] ([[anovulation|anovulatory]]) ||   30–100 µg/day 100–160 µg/day 320–640 µg/day 300 µg/day {{abbr|ND|No data}} ||   40–60 pg/mL 60–100 pg/mL 200–400 pg/mL 190 pg/mL 12–50 pg/mL ||   40–60 pg/mL {{abbr|ND|No data}} 170–200 pg/mL 100–150 pg/mL {{abbr|ND|No data}} ||   0.5–1 {{abbr|ND|No data}} 1–2 1.5 {{abbr|ND|No data}}
|-
| [[Menopause|Postmenopausal]] women || 18 µg/day || 5–20 pg/mL || 30–70 pg/mL || 0.3–0.8
|-
| [[Pregnancy|Pregnant]] women   [[First trimester]] (weeks 1–12)   [[Second trimester]] (weeks 13–26)   [[Third trimester]] (weeks 27–40) ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} ||   1,000–5,000 pg/mL 5,000–15,000 pg/mL 10,000–40,000 pg/mL ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}
|-
| Men || 20–60 µg/day || 27 (20–55) pg/mL || 20–90 pg/mL || 0.4–0.6
|-
! colspan="5" style="width: 1px;" | '''Notes:''' Mean levels are given as a single value and ranges are given after in parentheses. '''Sources:''' <ref name="pmid6717863">{{cite journal | vauthors = Nichols KC, Schenkel L, Benson H | title = 17 beta-estradiol for postmenopausal estrogen replacement therapy | journal = Obstet Gynecol Surv | volume = 39 | issue = 4 | pages = 230–45 | year = 1984 | pmid = 6717863 | doi = | url = }}</ref><ref name="CherneckyBerger2012_">{{cite book|author1=Cynthia C. Chernecky|author2=Barbara J. Berger|title=Laboratory Tests and Diagnostic Procedures – E-Book|url=https://books.google.com/books?id=dWHYcOJK-cgC&pg=PA488|date=31 October 2012|publisher=Elsevier Health Sciences|isbn=1-4557-4502-2|pages=488–}}</ref><ref name="pmid2992279">{{cite journal | vauthors = Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA | title = Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement | journal = Am. J. Obstet. Gynecol. | volume = 152 | issue = 8 | pages = 1099–106 | date = August 1985 | pmid = 2992279 | doi = 10.1016/0002-9378(85)90569-1 | url = }}</ref><ref name="Becker2001_">{{cite book|author=Kenneth L. Becker|title=Principles and Practice of Endocrinology and Metabolism|url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1059|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=889, 1059–1060, 2153}}</ref><ref name="BajajBerman2011_">{{cite book|author1=Lalit Bajaj|author2=Stephen Berman|title=Berman's Pediatric Decision Making|url=https://books.google.com/books?id=NPhnHrDQ1_kC&pg=PA160|date=1 January 2011|publisher=Elsevier Health Sciences|isbn=0-323-05405-6|pages=160–}}</ref><ref name="Abbott2009_">http://www.ilexmedical.com/files/PDF/Estradiol_ARC.pdf</ref><ref name="Kuhl2003_">{{cite journal | vauthors = Kuhl H | title = Östrogene für den Mann? | trans-title = Estrogens for the man? | journal = Blickpunkt der Mann | year = 2003 | volume = 1 | issue = 3 | pages = 6–12 | issn = 1727-0669 | doi = | pmid = | url = https://www.kup.at/journals/summary/3583.html}}</ref>
|}<noinclude>{{Documentation|content=
{{Improve documentation|date=March 2019}}
{{Accessibility dispute|date=March 2019}}
==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Endogenous estradiol production rates and plasma estrogen levels

2019-03-27T12:58:04Z

84.250.17.211: Table footer: Use tfoot for notes/references

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="text-align:left; margin-left:auto; margin-right:auto; border:none;"
|+ class="nowrap" | {{Navbar|Endogenous estradiol production rates and plasma estrogen levels|mini=y}} Endogenous <noinclude>[[estradiol (medication)|estradiol]]</noinclude><includeonly>estradiol</includeonly> production rates and plasma <noinclude>[[estrogen (medication)|estrogen]]</noinclude><includeonly>estrogen</includeonly> levels
|-
! Group !! {{abbr|E2|Estradiol}} ({{abbr|prod|production rate}}) !! {{abbr|E2|Estradiol}} (levels) !! {{abbr|E1|Estrone}} (levels) !! {{abbr|Ratio|Ratio (E2:E1)}}
|-
| [[Puberty|Pubertal]] girls   [[Tanner scale#Definitions of stages|Tanner stage I]] (childhood)   [[Tanner scale#Definitions of stages|Tanner stage II]] (ages 8–12)   [[Tanner scale#Definitions of stages|Tanner stage III]] (ages 10–13)   [[Tanner scale#Definitions of stages|Tanner stage IV]] (ages 11–14)   [[Tanner scale#Definitions of stages|Tanner stage V]] (ages 12–15)     [[Follicular phase|Follicular]] (days 1–14)     [[Luteal phase|Luteal]] (days 15–28) ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}   {{abbr|ND|No data}} {{abbr|ND|No data}} ||   9 (<9–20) pg/mL 15 (<9–30) pg/mL 27 (<9–60) pg/mL 55 (16–85) pg/mL   50 (30–100) pg/mL 130 (70–300) pg/mL ||   13 (<9–23) pg/mL 18 (10–37) pg/mL 26 (17–58) pg/mL 36 (23–69) pg/mL   44 (30–89) pg/mL 75 (39–160) pg/mL ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}   {{abbr|ND|No data}} {{abbr|ND|No data}}
|-
| [[Prepuberty|Prepubertal]] boys || {{abbr|ND|No data}} || 2–8 pg/mL || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[Premenopause|Premenopausal]] women   [[Follicular phase|Early follicular phase]] (days 1–4)   [[Follicular phase|Mid follicular phase]] (days 5–9)   [[Follicular phase|Late follicular phase]] (days 10–14)   [[Luteal phase]] (days 15–28)   [[Oral contraceptive]] ([[anovulation|anovulatory]]) ||   30–100 µg/day 100–160 µg/day 320–640 µg/day 300 µg/day {{abbr|ND|No data}} ||   40–60 pg/mL 60–100 pg/mL 200–400 pg/mL 190 pg/mL 12–50 pg/mL ||   40–60 pg/mL {{abbr|ND|No data}} 170–200 pg/mL 100–150 pg/mL {{abbr|ND|No data}} ||   0.5–1 {{abbr|ND|No data}} 1–2 1.5 {{abbr|ND|No data}}
|-
| [[Menopause|Postmenopausal]] women || 18 µg/day || 5–20 pg/mL || 30–70 pg/mL || 0.3–0.8
|-
| [[Pregnancy|Pregnant]] women   [[First trimester]] (weeks 1–12)   [[Second trimester]] (weeks 13–26)   [[Third trimester]] (weeks 27–40) ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} ||   1,000–5,000 pg/mL 5,000–15,000 pg/mL 10,000–40,000 pg/mL ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}
|-
| Men || 20–60 µg/day || 27 (20–55) pg/mL || 20–90 pg/mL || 0.4–0.6
|-
! colspan="5" style="width: 1px;" | '''Notes:''' Mean levels are given as a single value and ranges are given after in parentheses. '''Sources:''' <ref name="pmid6717863">{{cite journal | vauthors = Nichols KC, Schenkel L, Benson H | title = 17 beta-estradiol for postmenopausal estrogen replacement therapy | journal = Obstet Gynecol Surv | volume = 39 | issue = 4 | pages = 230–45 | year = 1984 | pmid = 6717863 | doi = | url = }}</ref><ref name="CherneckyBerger2012_">{{cite book|author1=Cynthia C. Chernecky|author2=Barbara J. Berger|title=Laboratory Tests and Diagnostic Procedures – E-Book|url=https://books.google.com/books?id=dWHYcOJK-cgC&pg=PA488|date=31 October 2012|publisher=Elsevier Health Sciences|isbn=1-4557-4502-2|pages=488–}}</ref><ref name="pmid2992279">{{cite journal | vauthors = Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA | title = Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement | journal = Am. J. Obstet. Gynecol. | volume = 152 | issue = 8 | pages = 1099–106 | date = August 1985 | pmid = 2992279 | doi = 10.1016/0002-9378(85)90569-1 | url = }}</ref><ref name="Becker2001_">{{cite book|author=Kenneth L. Becker|title=Principles and Practice of Endocrinology and Metabolism|url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1059|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=889, 1059–1060, 2153}}</ref><ref name="BajajBerman2011_">{{cite book|author1=Lalit Bajaj|author2=Stephen Berman|title=Berman's Pediatric Decision Making|url=https://books.google.com/books?id=NPhnHrDQ1_kC&pg=PA160|date=1 January 2011|publisher=Elsevier Health Sciences|isbn=0-323-05405-6|pages=160–}}</ref><ref name="Abbott2009_">http://www.ilexmedical.com/files/PDF/Estradiol_ARC.pdf</ref><ref name="Kuhl2003_">{{cite journal | vauthors = Kuhl H | title = Östrogene für den Mann? | trans-title = Estrogens for the man? | journal = Blickpunkt der Mann | year = 2003 | volume = 1 | issue = 3 | pages = 6–12 | issn = 1727-0669 | doi = | pmid = | url = https://www.kup.at/journals/summary/3583.html}}</ref>
|}<noinclude>{{Documentation|content=
{{Improve documentation|date=March 2019}}
{{Accessibility dispute|date=March 2019}}
==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Endogenous estradiol production rates and plasma estrogen levels

2019-03-27T12:54:23Z

84.250.17.211: Add Template:Accessibility dispute, date=March 2019

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="text-align:left; margin-left:auto; margin-right:auto; border:none;"
|+ class="nowrap" | {{Navbar|Endogenous estradiol production rates and plasma estrogen levels|mini=y}} Endogenous <noinclude>[[estradiol (medication)|estradiol]]</noinclude><includeonly>estradiol</includeonly> production rates and plasma <noinclude>[[estrogen (medication)|estrogen]]</noinclude><includeonly>estrogen</includeonly> levels
|-
! Group !! {{abbr|E2|Estradiol}} ({{abbr|prod|production rate}}) !! {{abbr|E2|Estradiol}} (levels) !! {{abbr|E1|Estrone}} (levels) !! {{abbr|Ratio|Ratio (E2:E1)}}
|-
| [[Puberty|Pubertal]] girls   [[Tanner scale#Definitions of stages|Tanner stage I]] (childhood)   [[Tanner scale#Definitions of stages|Tanner stage II]] (ages 8–12)   [[Tanner scale#Definitions of stages|Tanner stage III]] (ages 10–13)   [[Tanner scale#Definitions of stages|Tanner stage IV]] (ages 11–14)   [[Tanner scale#Definitions of stages|Tanner stage V]] (ages 12–15)     [[Follicular phase|Follicular]] (days 1–14)     [[Luteal phase|Luteal]] (days 15–28) ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}   {{abbr|ND|No data}} {{abbr|ND|No data}} ||   9 (<9–20) pg/mL 15 (<9–30) pg/mL 27 (<9–60) pg/mL 55 (16–85) pg/mL   50 (30–100) pg/mL 130 (70–300) pg/mL ||   13 (<9–23) pg/mL 18 (10–37) pg/mL 26 (17–58) pg/mL 36 (23–69) pg/mL   44 (30–89) pg/mL 75 (39–160) pg/mL ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}   {{abbr|ND|No data}} {{abbr|ND|No data}}
|-
| [[Prepuberty|Prepubertal]] boys || {{abbr|ND|No data}} || 2–8 pg/mL || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[Premenopause|Premenopausal]] women   [[Follicular phase|Early follicular phase]] (days 1–4)   [[Follicular phase|Mid follicular phase]] (days 5–9)   [[Follicular phase|Late follicular phase]] (days 10–14)   [[Luteal phase]] (days 15–28)   [[Oral contraceptive]] ([[anovulation|anovulatory]]) ||   30–100 µg/day 100–160 µg/day 320–640 µg/day 300 µg/day {{abbr|ND|No data}} ||   40–60 pg/mL 60–100 pg/mL 200–400 pg/mL 190 pg/mL 12–50 pg/mL ||   40–60 pg/mL {{abbr|ND|No data}} 170–200 pg/mL 100–150 pg/mL {{abbr|ND|No data}} ||   0.5–1 {{abbr|ND|No data}} 1–2 1.5 {{abbr|ND|No data}}
|-
| [[Menopause|Postmenopausal]] women || 18 µg/day || 5–20 pg/mL || 30–70 pg/mL || 0.3–0.8
|-
| [[Pregnancy|Pregnant]] women   [[First trimester]] (weeks 1–12)   [[Second trimester]] (weeks 13–26)   [[Third trimester]] (weeks 27–40) ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} ||   1,000–5,000 pg/mL 5,000–15,000 pg/mL 10,000–40,000 pg/mL ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}
|-
| Men || 20–60 µg/day || 27 (20–55) pg/mL || 20–90 pg/mL || 0.4–0.6
|- class="sortbottom"
| colspan="5" style="width: 1px;" | '''Notes:''' Mean levels are given as a single value and ranges are given after in parentheses. '''Sources:''' <ref name="pmid6717863">{{cite journal | vauthors = Nichols KC, Schenkel L, Benson H | title = 17 beta-estradiol for postmenopausal estrogen replacement therapy | journal = Obstet Gynecol Surv | volume = 39 | issue = 4 | pages = 230–45 | year = 1984 | pmid = 6717863 | doi = | url = }}</ref><ref name="CherneckyBerger2012_">{{cite book|author1=Cynthia C. Chernecky|author2=Barbara J. Berger|title=Laboratory Tests and Diagnostic Procedures – E-Book|url=https://books.google.com/books?id=dWHYcOJK-cgC&pg=PA488|date=31 October 2012|publisher=Elsevier Health Sciences|isbn=1-4557-4502-2|pages=488–}}</ref><ref name="pmid2992279">{{cite journal | vauthors = Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA | title = Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement | journal = Am. J. Obstet. Gynecol. | volume = 152 | issue = 8 | pages = 1099–106 | date = August 1985 | pmid = 2992279 | doi = 10.1016/0002-9378(85)90569-1 | url = }}</ref><ref name="Becker2001_">{{cite book|author=Kenneth L. Becker|title=Principles and Practice of Endocrinology and Metabolism|url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1059|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=889, 1059–1060, 2153}}</ref><ref name="BajajBerman2011_">{{cite book|author1=Lalit Bajaj|author2=Stephen Berman|title=Berman's Pediatric Decision Making|url=https://books.google.com/books?id=NPhnHrDQ1_kC&pg=PA160|date=1 January 2011|publisher=Elsevier Health Sciences|isbn=0-323-05405-6|pages=160–}}</ref><ref name="Abbott2009_">http://www.ilexmedical.com/files/PDF/Estradiol_ARC.pdf</ref><ref name="Kuhl2003_">{{cite journal | vauthors = Kuhl H | title = Östrogene für den Mann? | trans-title = Estrogens for the man? | journal = Blickpunkt der Mann | year = 2003 | volume = 1 | issue = 3 | pages = 6–12 | issn = 1727-0669 | doi = | pmid = | url = https://www.kup.at/journals/summary/3583.html}}</ref>
|}<noinclude>{{Documentation|content=
{{Improve documentation|date=March 2019}}
{{Accessibility dispute|date=March 2019}}
==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Endogenous estradiol production rates and plasma estrogen levels

2019-03-27T12:53:59Z

84.250.17.211: Add Template:Improve documentation, date=March 2019

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="text-align:left; margin-left:auto; margin-right:auto; border:none;"
|+ class="nowrap" | {{Navbar|Endogenous estradiol production rates and plasma estrogen levels|mini=y}} Endogenous <noinclude>[[estradiol (medication)|estradiol]]</noinclude><includeonly>estradiol</includeonly> production rates and plasma <noinclude>[[estrogen (medication)|estrogen]]</noinclude><includeonly>estrogen</includeonly> levels
|-
! Group !! {{abbr|E2|Estradiol}} ({{abbr|prod|production rate}}) !! {{abbr|E2|Estradiol}} (levels) !! {{abbr|E1|Estrone}} (levels) !! {{abbr|Ratio|Ratio (E2:E1)}}
|-
| [[Puberty|Pubertal]] girls   [[Tanner scale#Definitions of stages|Tanner stage I]] (childhood)   [[Tanner scale#Definitions of stages|Tanner stage II]] (ages 8–12)   [[Tanner scale#Definitions of stages|Tanner stage III]] (ages 10–13)   [[Tanner scale#Definitions of stages|Tanner stage IV]] (ages 11–14)   [[Tanner scale#Definitions of stages|Tanner stage V]] (ages 12–15)     [[Follicular phase|Follicular]] (days 1–14)     [[Luteal phase|Luteal]] (days 15–28) ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}   {{abbr|ND|No data}} {{abbr|ND|No data}} ||   9 (<9–20) pg/mL 15 (<9–30) pg/mL 27 (<9–60) pg/mL 55 (16–85) pg/mL   50 (30–100) pg/mL 130 (70–300) pg/mL ||   13 (<9–23) pg/mL 18 (10–37) pg/mL 26 (17–58) pg/mL 36 (23–69) pg/mL   44 (30–89) pg/mL 75 (39–160) pg/mL ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}   {{abbr|ND|No data}} {{abbr|ND|No data}}
|-
| [[Prepuberty|Prepubertal]] boys || {{abbr|ND|No data}} || 2–8 pg/mL || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[Premenopause|Premenopausal]] women   [[Follicular phase|Early follicular phase]] (days 1–4)   [[Follicular phase|Mid follicular phase]] (days 5–9)   [[Follicular phase|Late follicular phase]] (days 10–14)   [[Luteal phase]] (days 15–28)   [[Oral contraceptive]] ([[anovulation|anovulatory]]) ||   30–100 µg/day 100–160 µg/day 320–640 µg/day 300 µg/day {{abbr|ND|No data}} ||   40–60 pg/mL 60–100 pg/mL 200–400 pg/mL 190 pg/mL 12–50 pg/mL ||   40–60 pg/mL {{abbr|ND|No data}} 170–200 pg/mL 100–150 pg/mL {{abbr|ND|No data}} ||   0.5–1 {{abbr|ND|No data}} 1–2 1.5 {{abbr|ND|No data}}
|-
| [[Menopause|Postmenopausal]] women || 18 µg/day || 5–20 pg/mL || 30–70 pg/mL || 0.3–0.8
|-
| [[Pregnancy|Pregnant]] women   [[First trimester]] (weeks 1–12)   [[Second trimester]] (weeks 13–26)   [[Third trimester]] (weeks 27–40) ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} ||   1,000–5,000 pg/mL 5,000–15,000 pg/mL 10,000–40,000 pg/mL ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}
|-
| Men || 20–60 µg/day || 27 (20–55) pg/mL || 20–90 pg/mL || 0.4–0.6
|- class="sortbottom"
| colspan="5" style="width: 1px;" | '''Notes:''' Mean levels are given as a single value and ranges are given after in parentheses. '''Sources:''' <ref name="pmid6717863">{{cite journal | vauthors = Nichols KC, Schenkel L, Benson H | title = 17 beta-estradiol for postmenopausal estrogen replacement therapy | journal = Obstet Gynecol Surv | volume = 39 | issue = 4 | pages = 230–45 | year = 1984 | pmid = 6717863 | doi = | url = }}</ref><ref name="CherneckyBerger2012_">{{cite book|author1=Cynthia C. Chernecky|author2=Barbara J. Berger|title=Laboratory Tests and Diagnostic Procedures – E-Book|url=https://books.google.com/books?id=dWHYcOJK-cgC&pg=PA488|date=31 October 2012|publisher=Elsevier Health Sciences|isbn=1-4557-4502-2|pages=488–}}</ref><ref name="pmid2992279">{{cite journal | vauthors = Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA | title = Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement | journal = Am. J. Obstet. Gynecol. | volume = 152 | issue = 8 | pages = 1099–106 | date = August 1985 | pmid = 2992279 | doi = 10.1016/0002-9378(85)90569-1 | url = }}</ref><ref name="Becker2001_">{{cite book|author=Kenneth L. Becker|title=Principles and Practice of Endocrinology and Metabolism|url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1059|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=889, 1059–1060, 2153}}</ref><ref name="BajajBerman2011_">{{cite book|author1=Lalit Bajaj|author2=Stephen Berman|title=Berman's Pediatric Decision Making|url=https://books.google.com/books?id=NPhnHrDQ1_kC&pg=PA160|date=1 January 2011|publisher=Elsevier Health Sciences|isbn=0-323-05405-6|pages=160–}}</ref><ref name="Abbott2009_">http://www.ilexmedical.com/files/PDF/Estradiol_ARC.pdf</ref><ref name="Kuhl2003_">{{cite journal | vauthors = Kuhl H | title = Östrogene für den Mann? | trans-title = Estrogens for the man? | journal = Blickpunkt der Mann | year = 2003 | volume = 1 | issue = 3 | pages = 6–12 | issn = 1727-0669 | doi = | pmid = | url = https://www.kup.at/journals/summary/3583.html}}</ref>
|}<noinclude>{{Documentation|content=
{{Improve documentation|date=March 2019}}
==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Endogenous estradiol production rates and plasma estrogen levels

2019-03-27T12:53:43Z

84.250.17.211: Add inline Template:Documentation; wrap references into it

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="text-align:left; margin-left:auto; margin-right:auto; border:none;"
|+ class="nowrap" | {{Navbar|Endogenous estradiol production rates and plasma estrogen levels|mini=y}} Endogenous <noinclude>[[estradiol (medication)|estradiol]]</noinclude><includeonly>estradiol</includeonly> production rates and plasma <noinclude>[[estrogen (medication)|estrogen]]</noinclude><includeonly>estrogen</includeonly> levels
|-
! Group !! {{abbr|E2|Estradiol}} ({{abbr|prod|production rate}}) !! {{abbr|E2|Estradiol}} (levels) !! {{abbr|E1|Estrone}} (levels) !! {{abbr|Ratio|Ratio (E2:E1)}}
|-
| [[Puberty|Pubertal]] girls   [[Tanner scale#Definitions of stages|Tanner stage I]] (childhood)   [[Tanner scale#Definitions of stages|Tanner stage II]] (ages 8–12)   [[Tanner scale#Definitions of stages|Tanner stage III]] (ages 10–13)   [[Tanner scale#Definitions of stages|Tanner stage IV]] (ages 11–14)   [[Tanner scale#Definitions of stages|Tanner stage V]] (ages 12–15)     [[Follicular phase|Follicular]] (days 1–14)     [[Luteal phase|Luteal]] (days 15–28) ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}   {{abbr|ND|No data}} {{abbr|ND|No data}} ||   9 (<9–20) pg/mL 15 (<9–30) pg/mL 27 (<9–60) pg/mL 55 (16–85) pg/mL   50 (30–100) pg/mL 130 (70–300) pg/mL ||   13 (<9–23) pg/mL 18 (10–37) pg/mL 26 (17–58) pg/mL 36 (23–69) pg/mL   44 (30–89) pg/mL 75 (39–160) pg/mL ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}   {{abbr|ND|No data}} {{abbr|ND|No data}}
|-
| [[Prepuberty|Prepubertal]] boys || {{abbr|ND|No data}} || 2–8 pg/mL || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[Premenopause|Premenopausal]] women   [[Follicular phase|Early follicular phase]] (days 1–4)   [[Follicular phase|Mid follicular phase]] (days 5–9)   [[Follicular phase|Late follicular phase]] (days 10–14)   [[Luteal phase]] (days 15–28)   [[Oral contraceptive]] ([[anovulation|anovulatory]]) ||   30–100 µg/day 100–160 µg/day 320–640 µg/day 300 µg/day {{abbr|ND|No data}} ||   40–60 pg/mL 60–100 pg/mL 200–400 pg/mL 190 pg/mL 12–50 pg/mL ||   40–60 pg/mL {{abbr|ND|No data}} 170–200 pg/mL 100–150 pg/mL {{abbr|ND|No data}} ||   0.5–1 {{abbr|ND|No data}} 1–2 1.5 {{abbr|ND|No data}}
|-
| [[Menopause|Postmenopausal]] women || 18 µg/day || 5–20 pg/mL || 30–70 pg/mL || 0.3–0.8
|-
| [[Pregnancy|Pregnant]] women   [[First trimester]] (weeks 1–12)   [[Second trimester]] (weeks 13–26)   [[Third trimester]] (weeks 27–40) ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} ||   1,000–5,000 pg/mL 5,000–15,000 pg/mL 10,000–40,000 pg/mL ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}} ||   {{abbr|ND|No data}} {{abbr|ND|No data}} {{abbr|ND|No data}}
|-
| Men || 20–60 µg/day || 27 (20–55) pg/mL || 20–90 pg/mL || 0.4–0.6
|- class="sortbottom"
| colspan="5" style="width: 1px;" | '''Notes:''' Mean levels are given as a single value and ranges are given after in parentheses. '''Sources:''' <ref name="pmid6717863">{{cite journal | vauthors = Nichols KC, Schenkel L, Benson H | title = 17 beta-estradiol for postmenopausal estrogen replacement therapy | journal = Obstet Gynecol Surv | volume = 39 | issue = 4 | pages = 230–45 | year = 1984 | pmid = 6717863 | doi = | url = }}</ref><ref name="CherneckyBerger2012_">{{cite book|author1=Cynthia C. Chernecky|author2=Barbara J. Berger|title=Laboratory Tests and Diagnostic Procedures – E-Book|url=https://books.google.com/books?id=dWHYcOJK-cgC&pg=PA488|date=31 October 2012|publisher=Elsevier Health Sciences|isbn=1-4557-4502-2|pages=488–}}</ref><ref name="pmid2992279">{{cite journal | vauthors = Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA | title = Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement | journal = Am. J. Obstet. Gynecol. | volume = 152 | issue = 8 | pages = 1099–106 | date = August 1985 | pmid = 2992279 | doi = 10.1016/0002-9378(85)90569-1 | url = }}</ref><ref name="Becker2001_">{{cite book|author=Kenneth L. Becker|title=Principles and Practice of Endocrinology and Metabolism|url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1059|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=889, 1059–1060, 2153}}</ref><ref name="BajajBerman2011_">{{cite book|author1=Lalit Bajaj|author2=Stephen Berman|title=Berman's Pediatric Decision Making|url=https://books.google.com/books?id=NPhnHrDQ1_kC&pg=PA160|date=1 January 2011|publisher=Elsevier Health Sciences|isbn=0-323-05405-6|pages=160–}}</ref><ref name="Abbott2009_">http://www.ilexmedical.com/files/PDF/Estradiol_ARC.pdf</ref><ref name="Kuhl2003_">{{cite journal | vauthors = Kuhl H | title = Östrogene für den Mann? | trans-title = Estrogens for the man? | journal = Blickpunkt der Mann | year = 2003 | volume = 1 | issue = 3 | pages = 6–12 | issn = 1727-0669 | doi = | pmid = | url = https://www.kup.at/journals/summary/3583.html}}</ref>
|}<noinclude>{{Documentation|content=
==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Antiandrogens marketed for clinical or veterinary use

2019-03-27T11:50:10Z

84.250.17.211: Table footer: Use tfoot for notes/references

Template:Major estrogens marketed for clinical or veterinary use

2019-03-27T11:49:51Z

84.250.17.211: Table footer: Use tfoot for notes/references

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="font-size:small; margin-left: auto; margin-right: auto; border: none;"
|+ class="nowrap" | {{Navbar|Major estrogens marketed for clinical or veterinary use|mini=y}} {{Resize|105%|Major {{No selflink|estrogen (medication)|estrogen}}s marketed for clinical or veterinary use}}
|-
! Generic name !! Class !! Brand name(s) !! Route(s) !! Launch !! Status !! {{abbr|Hits|Google Search hits (February 2018)}}a
|-
| [[Chlorotrianisene]] || data-sort-value="Steroidal_, Non" | Nonsteroidal || Tace, others || Oral || 1952 || Discontinued || 473,000
|-
| [[Conjugated estrogens]] || data-sort-value="Steroidal; _Equine, Ester" | Steroidal; Equine; Ester || Premarin || Oral, others || 1941 || Available || 2,800,000
|-
| [[Dienestrol]] || data-sort-value="Steroidal_, Non" | Nonsteroidal || Numerous || Oral || 1947 || Availableb || 527,000
|-
| [[Diethylstilbestrol]] || data-sort-value="Steroidal_, Non" | Nonsteroidal || Stilbestrol, others || Oral, others || 1941 || Availableb || 560,000
|-
| [[Diethylstilbestrol dipropionate]] || data-sort-value="Steroidal_, Non, Ester" | Nonsteroidal; Ester || Numerous || {{abbr|IM|Intramuscular injection}} || 1940s || Discontinued || 2,790
|-
| [[Esterified estrogens]] || data-sort-value="Steroidal; _Equine, Ester" | Steroidal; Equine; Ester || Estratab || Oral || 1970 || Available || 113,000
|-
| [[Estetrol (medication)|Estetrol]] || data-sort-value="Steroidal" | Steroidal || Donesta, Estelle || Oral || Phase III || Experimental || 24,000
|-
| [[Estradiol (medication)|Estradiol]] || data-sort-value="Steroidal" | Steroidal || Estrace, numerous others || Many || 1930s || Available || 9,720,000
|-
| [[Estradiol acetate]] || data-sort-value="Steroidal, Ester" | Steroidal; Ester || Femtrace, Femring, Menoring || Oral, vaginal || 2001 || Available || 50,900
|-
| [[Estradiol benzoate]] || data-sort-value="Steroidal, Ester" | Steroidal; Ester || Progynon-B || {{abbr|IM|Intramuscular injection}} || 1936 || Available || 177,000
|-
| [[Estradiol cypionate]] || data-sort-value="Steroidal, Ester" | Steroidal; Ester || Depo-Estradiol || {{abbr|IM|Intramuscular injection}} || 1952 || Available || 75,900
|-
| [[Estradiol dipropionate]] || data-sort-value="Steroidal, Ester" | Steroidal; Ester || Agofollin, Di-Ovocyclin, Progynon DP || {{abbr|IM|Intramuscular injection}} || 1940 || Discontinued || 12,400
|-
| [[Estradiol enantate]] || data-sort-value="Steroidal, Ester" | Steroidal; Ester || Deladroxate, Perlutan, Topasel || {{abbr|IM|Intramuscular injection}} || 1964 || Available || 44,600
|-
| [[Estradiol undecylate]] || data-sort-value="Steroidal, Ester" | Steroidal; Ester || Progynon Depot 100 || {{abbr|IM|Intramuscular injection}} || 1956 || Discontinued || 8,250
|-
| [[Estradiol valerate]] || data-sort-value="Steroidal, Ester" | Steroidal; Ester || Progynova, Progynon Depot, Delestrogen || Oral, {{abbr|IM|Intramuscular injection}} || 1954 || Available || 2,200,000
|-
| [[Estramustine phosphate]] || data-sort-value="Steroidal, Ester; Cytostatic" | Steroidal; Ester; Cytostatic || Emcyt, Estracyt || Oral || 1970s || Available || 237,000
|-
| [[Estriol (medication)|Estriol]] || data-sort-value="Steroidal" | Steroidal || Ovestin || Oral, vaginal || 1930s || Available || 8,930,000
|-
| [[Estrone (medication)|Estrone]] || data-sort-value="Steroidal" | Steroidal || Theelin, Progynon || {{abbr|IM|Intramuscular injection}} || 1930s || Discontinued || 850,000
|-
| [[Estropipate]] || data-sort-value="Steroidal, Ester" | Steroidal; Ester || Ogen || Oral || 1968 || Availableb || 214,000
|-
| [[Ethinylestradiol]] || data-sort-value="Steroidal; Alkyl" | Steroidal; Alkyl || Estinyl, numerous others || Oral, others || 1943 || Available || 1,780,000
|-
| [[Ethinylestradiol sulfonate]] || data-sort-value="Steroidal; Alkyl, Ester" | Steroidal; Alkyl; Ester|| Turisteron || Oral || 1980s || Discontinued || 10,900
|-
| [[Fosfestrol]] || data-sort-value="Steroidal_, Non, Ester" | Nonsteroidal; Ester || Honvan, others || {{abbr|IM|Intramuscular injection}} || 1947 || Availableb || 115,000
|-
| [[Hexestrol]] || data-sort-value="Steroidal_, Non" | Nonsteroidal || Synestrol, others || Oral, others || 1940s || Availableb || 171,000
|-
| [[Mestranol]] || data-sort-value="Steroidal; Alkyl, Ether" | Steroidal; Alkyl; Ether || Numerous || Oral || 1957 || Availableb || 169,000
|-
| [[Methallenestril]] || data-sort-value="Steroidal_, Non, Ether" | Nonsteroidal; Ether || Vallestril || Oral || 1950s || Discontinued || 35,300
|-
| [[Methylestradiol]] || data-sort-value="Steroidal; Alkyl" | Steroidal; Alkyl || Ginecosid, others || Oral || ? || Availableb || 10,500
|-
| [[Moxestrol]] || data-sort-value="Steroidal; Alkyl" | Steroidal; Alkyl || Surestryl || Oral || 1970s || Discontinued || 9,510
|-
| [[Polyestradiol phosphate]] || data-sort-value="Steroidal, Ester, Polymer" | Steroidal; Ester; Polymer || Estradurin || {{abbr|IM|Intramuscular injection}} || 1957 || Availableb || 124,000
|-
| [[Prasterone|Prasterone ({{abbr|DHEA|dehydroepiandrosterone}})]] || data-sort-value="Steroidal, Prohormone" | Steroidal; Prohormone || Numerous || Many || 1970s || Available || 11,600,000
|-
| [[Quinestrol]] || data-sort-value="Steroidal; Alkyl, Ether" | Steroidal; Alkyl; Ether || Estrovis || Oral || 1960s || Discontinued || 23,800
|-
| [[Zeranol]] || data-sort-value="Steroidal_, Non" | Nonsteroidal || Ralgro, others || Veterinary || 1970s || Veterinary || 91,800
|-
! colspan="7" style="width: 1px;" | '''Footnotes:''' a = Hits = Google Search hits (as of February 2018). b = Availability limited / mostly discontinued. '''Class:''' Steroidal = [[Steroidal estrogen]]. Nonsteroidal = [[Nonsteroidal estrogen]]. Alkyl = 17α-Alkylated. Cytostatic = [[Chemotherapeutic agent]]. '''Sources:''' See individual articles.
|}<noinclude>
[[Category:Medication templates]]
</noinclude>

Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative

2019-03-27T11:40:53Z

84.250.17.211: /* Documentation */ Move notes to top (above references)

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
|-
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}{{NoteTag|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}}) !! style="width: 75px;" data-sort-type="number" | Placebo (n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} (n = 8506)
|-
! colspan="2" | Absolute Risk per 10,000 Women-Years
|-
| [[Coronary heart disease]] events ({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) || 30 23 6 || 37 30 7
|-
| [[Invasive breast cancer]]{{efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38
|-
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
|-
| [[Pulmonary embolism]] || 2.13 (1.39–3.25) || 8 || 16
|-
| [[Colorectal cancer]] || 0.63 (0.43–0.92) || 16 || 10
|-
| [[Endometrial cancer]] || 0.83 (0.47–1.47) || 6 || 5
|-
| [[Hip fracture]] || 0.66 (0.45–0.98) || 15 || 10
|-
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
|-
| Global Index{{efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170
|-
| [[Deep vein thrombosis]]{{efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26
|-
| [[Vertebral fracture]]s{{efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9
|-
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
|-
! colspan="10" | Sources: <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
|}<noinclude>{{Documentation|content=
{{Improve documentation|date=March 2019}}
==Notes and references==
{{Notelist}}
{{Notefoot}}
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative

2019-03-27T11:39:48Z

84.250.17.211: Remove now unnecessary 1px width hack from table footer cell

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
|-
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}{{NoteTag|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}}) !! style="width: 75px;" data-sort-type="number" | Placebo (n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} (n = 8506)
|-
! colspan="2" | Absolute Risk per 10,000 Women-Years
|-
| [[Coronary heart disease]] events ({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) || 30 23 6 || 37 30 7
|-
| [[Invasive breast cancer]]{{efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38
|-
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
|-
| [[Pulmonary embolism]] || 2.13 (1.39–3.25) || 8 || 16
|-
| [[Colorectal cancer]] || 0.63 (0.43–0.92) || 16 || 10
|-
| [[Endometrial cancer]] || 0.83 (0.47–1.47) || 6 || 5
|-
| [[Hip fracture]] || 0.66 (0.45–0.98) || 15 || 10
|-
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
|-
| Global Index{{efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170
|-
| [[Deep vein thrombosis]]{{efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26
|-
| [[Vertebral fracture]]s{{efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9
|-
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
|-
! colspan="10" | Sources: <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
|}<noinclude>{{Documentation|content=
{{Improve documentation|date=March 2019}}
==Notes and references==
{{Reflist}}
{{Notelist}}
{{Notefoot}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative

2019-03-27T11:39:22Z

84.250.17.211: Sources list: Remove boldness () around "Sources:" word, seems just slightly unnecessary (for what's not really a heading, anyway)

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
|-
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}{{NoteTag|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}}) !! style="width: 75px;" data-sort-type="number" | Placebo (n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} (n = 8506)
|-
! colspan="2" | Absolute Risk per 10,000 Women-Years
|-
| [[Coronary heart disease]] events ({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) || 30 23 6 || 37 30 7
|-
| [[Invasive breast cancer]]{{efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38
|-
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
|-
| [[Pulmonary embolism]] || 2.13 (1.39–3.25) || 8 || 16
|-
| [[Colorectal cancer]] || 0.63 (0.43–0.92) || 16 || 10
|-
| [[Endometrial cancer]] || 0.83 (0.47–1.47) || 6 || 5
|-
| [[Hip fracture]] || 0.66 (0.45–0.98) || 15 || 10
|-
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
|-
| Global Index{{efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170
|-
| [[Deep vein thrombosis]]{{efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26
|-
| [[Vertebral fracture]]s{{efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9
|-
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
|-
! colspan="10" style="width: 1px;" | Sources: <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
|}<noinclude>{{Documentation|content=
{{Improve documentation|date=March 2019}}
==Notes and references==
{{Reflist}}
{{Notelist}}
{{Notefoot}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative

2019-03-27T11:37:04Z

84.250.17.211: Sources list: Use table footer element instead of table data cell for accessibility

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
|-
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}{{NoteTag|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}}) !! style="width: 75px;" data-sort-type="number" | Placebo (n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} (n = 8506)
|-
! colspan="2" | Absolute Risk per 10,000 Women-Years
|-
| [[Coronary heart disease]] events ({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) || 30 23 6 || 37 30 7
|-
| [[Invasive breast cancer]]{{efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38
|-
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
|-
| [[Pulmonary embolism]] || 2.13 (1.39–3.25) || 8 || 16
|-
| [[Colorectal cancer]] || 0.63 (0.43–0.92) || 16 || 10
|-
| [[Endometrial cancer]] || 0.83 (0.47–1.47) || 6 || 5
|-
| [[Hip fracture]] || 0.66 (0.45–0.98) || 15 || 10
|-
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
|-
| Global Index{{efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170
|-
| [[Deep vein thrombosis]]{{efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26
|-
| [[Vertebral fracture]]s{{efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9
|-
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
|-
! colspan="10" style="width: 1px;" | '''Sources:''' <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
|}<noinclude>{{Documentation|content=
{{Improve documentation|date=March 2019}}
==Notes and references==
{{Reflist}}
{{Notelist}}
{{Notefoot}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative

2019-03-27T09:54:53Z

84.250.17.211: Add Template:Improve documentation, date=March 2019: May need to mention it needs Template:Notelist and such.

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
|-
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}{{NoteTag|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}}) !! style="width: 75px;" data-sort-type="number" | Placebo (n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} (n = 8506)
|-
! colspan="2" | Absolute Risk per 10,000 Women-Years
|-
| [[Coronary heart disease]] events ({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) || 30 23 6 || 37 30 7
|-
| [[Invasive breast cancer]]{{efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38
|-
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
|-
| [[Pulmonary embolism]] || 2.13 (1.39–3.25) || 8 || 16
|-
| [[Colorectal cancer]] || 0.63 (0.43–0.92) || 16 || 10
|-
| [[Endometrial cancer]] || 0.83 (0.47–1.47) || 6 || 5
|-
| [[Hip fracture]] || 0.66 (0.45–0.98) || 15 || 10
|-
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
|-
| Global Index{{efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170
|-
| [[Deep vein thrombosis]]{{efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26
|-
| [[Vertebral fracture]]s{{efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9
|-
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
|- class="sortbottom"
| colspan="10" style="width: 1px;" | '''Sources:''' <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
|}<noinclude>{{Documentation|content=
{{Improve documentation|date=March 2019}}
==Notes and references==
{{Reflist}}
{{Notelist}}
{{Notefoot}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative

2019-03-27T09:54:27Z

84.250.17.211: Add inline Template:Documentation; wrap notes and references into it

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
|-
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}{{NoteTag|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}}) !! style="width: 75px;" data-sort-type="number" | Placebo (n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} (n = 8506)
|-
! colspan="2" | Absolute Risk per 10,000 Women-Years
|-
| [[Coronary heart disease]] events ({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) || 30 23 6 || 37 30 7
|-
| [[Invasive breast cancer]]{{efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38
|-
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
|-
| [[Pulmonary embolism]] || 2.13 (1.39–3.25) || 8 || 16
|-
| [[Colorectal cancer]] || 0.63 (0.43–0.92) || 16 || 10
|-
| [[Endometrial cancer]] || 0.83 (0.47–1.47) || 6 || 5
|-
| [[Hip fracture]] || 0.66 (0.45–0.98) || 15 || 10
|-
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
|-
| Global Index{{efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170
|-
| [[Deep vein thrombosis]]{{efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26
|-
| [[Vertebral fracture]]s{{efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9
|-
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
|- class="sortbottom"
| colspan="10" style="width: 1px;" | '''Sources:''' <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
|}<noinclude>{{Documentation|content=
==Notes and references==
{{Reflist}}
{{Notelist}}
{{Notefoot}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative

2019-03-27T09:30:44Z

84.250.17.211: Remove abbreviations from table cell: Already marked up with Template:Abbr for screen readers.

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
|-
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}{{NoteTag|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}}) !! style="width: 75px;" data-sort-type="number" | Placebo (n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} (n = 8506)
|-
! colspan="2" | Absolute Risk per 10,000 Women-Years
|-
| [[Coronary heart disease]] events ({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) || 30 23 6 || 37 30 7
|-
| [[Invasive breast cancer]]{{efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38
|-
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
|-
| [[Pulmonary embolism]] || 2.13 (1.39–3.25) || 8 || 16
|-
| [[Colorectal cancer]] || 0.63 (0.43–0.92) || 16 || 10
|-
| [[Endometrial cancer]] || 0.83 (0.47–1.47) || 6 || 5
|-
| [[Hip fracture]] || 0.66 (0.45–0.98) || 15 || 10
|-
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
|-
| Global Index{{efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170
|-
| [[Deep vein thrombosis]]{{efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26
|-
| [[Vertebral fracture]]s{{efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9
|-
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
|- class="sortbottom"
| colspan="10" style="width: 1px;" | '''Sources:''' <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
|}<noinclude>
==Notes and references==
{{Reflist}}
{{Notelist}}
{{Notefoot}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative

2019-03-27T09:27:32Z

84.250.17.211: Replace pseudo-footnote with ref-tag footnotes (MOS:NOTES)

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
|-
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}{{NoteTag|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}}) !! style="width: 75px;" data-sort-type="number" | Placebo (n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} (n = 8506)
|-
! colspan="2" | Absolute Risk per 10,000 Women-Years
|-
| [[Coronary heart disease]] events ({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) || 30 23 6 || 37 30 7
|-
| [[Invasive breast cancer]]{{efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38
|-
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
|-
| [[Pulmonary embolism]] || 2.13 (1.39–3.25) || 8 || 16
|-
| [[Colorectal cancer]] || 0.63 (0.43–0.92) || 16 || 10
|-
| [[Endometrial cancer]] || 0.83 (0.47–1.47) || 6 || 5
|-
| [[Hip fracture]] || 0.66 (0.45–0.98) || 15 || 10
|-
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
|-
| Global Index{{efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170
|-
| [[Deep vein thrombosis]]{{efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26
|-
| [[Vertebral fracture]]s{{efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9
|-
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
|- class="sortbottom"
| colspan="10" style="width: 1px;" | '''Abbreviations:''' WHI = {{No selflink|Women's Health Initiative}}. CEEs = {{No selflink|Conjugated estrogens}}. MPA = {{No selflink|Medroxyprogesterone acetate}}. '''Notes:''' Dosages were 0.625 mg/day CEEs and 2.5 mg/day MPA. '''Sources:''' <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
|}<noinclude>
==Notes and references==
{{Reflist}}
{{Notelist}}
{{Notefoot}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative

2019-03-27T09:18:30Z

84.250.17.211: Coronary heart disease events: One line break ought to be enough with parenthesis around. Template:Dfn to assist screen readers.

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
|-
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}*) !! style="width: 75px;" data-sort-type="number" | Placebo (n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} (n = 8506)
|-
! colspan="2" | Absolute Risk per 10,000 Women-Years
|-
| [[Coronary heart disease]] events ({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) || 30 23 6 || 37 30 7
|-
| [[Invasive breast cancer]]a || 1.26 (1.00–1.59) || 30 || 38
|-
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
|-
| [[Pulmonary embolism]] || 2.13 (1.39–3.25) || 8 || 16
|-
| [[Colorectal cancer]] || 0.63 (0.43–0.92) || 16 || 10
|-
| [[Endometrial cancer]] || 0.83 (0.47–1.47) || 6 || 5
|-
| [[Hip fracture]] || 0.66 (0.45–0.98) || 15 || 10
|-
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
|-
| Global Indexb || 1.15 (1.03–1.28) || 151 || 170
|-
| [[Deep vein thrombosis]]c || 2.07 (1.49–2.87) || 13 || 26
|-
| [[Vertebral fracture]]sc || 0.66 (0.44–0.98) || 15 || 9
|-
| Other [[osteoporotic fracture]]sc || 0.77 (0.69–0.86) || 170 || 131
|- class="sortbottom"
| colspan="10" style="width: 1px;" | '''Abbreviations:''' WHI = {{No selflink|Women's Health Initiative}}. CEEs = {{No selflink|Conjugated estrogens}}. MPA = {{No selflink|Medroxyprogesterone acetate}}. '''Notes:''' Dosages were 0.625 mg/day CEEs and 2.5 mg/day MPA. '''Footnotes:''' a = Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer. b = A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes. c = Not included in Global Index. * = Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. '''Sources:''' <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
|}<noinclude>
==References==
{{Reflist}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative

2019-03-27T08:37:30Z

84.250.17.211: Remove inline styling from table: Prone to not displaying well on low width resolution displays, especially with margins.

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
|-
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}*) !! style="width: 75px;" data-sort-type="number" | Placebo (n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} (n = 8506)
|-
! colspan="2" | Absolute Risk per 10,000 Women-Years
|-
| [[Coronary heart disease]] events   Non-fatal [[myocardial infarction]]   Coronary heart disease death || 1.29 (1.02–1.63) 1.32 (1.02–1.72) 1.18 (0.70–1.97) || 30 23 6 || 37 30 7
|-
| [[Invasive breast cancer]]a || 1.26 (1.00–1.59) || 30 || 38
|-
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
|-
| [[Pulmonary embolism]] || 2.13 (1.39–3.25) || 8 || 16
|-
| [[Colorectal cancer]] || 0.63 (0.43–0.92) || 16 || 10
|-
| [[Endometrial cancer]] || 0.83 (0.47–1.47) || 6 || 5
|-
| [[Hip fracture]] || 0.66 (0.45–0.98) || 15 || 10
|-
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
|-
| Global Indexb || 1.15 (1.03–1.28) || 151 || 170
|-
| [[Deep vein thrombosis]]c || 2.07 (1.49–2.87) || 13 || 26
|-
| [[Vertebral fracture]]sc || 0.66 (0.44–0.98) || 15 || 9
|-
| Other [[osteoporotic fracture]]sc || 0.77 (0.69–0.86) || 170 || 131
|- class="sortbottom"
| colspan="10" style="width: 1px;" | '''Abbreviations:''' WHI = {{No selflink|Women's Health Initiative}}. CEEs = {{No selflink|Conjugated estrogens}}. MPA = {{No selflink|Medroxyprogesterone acetate}}. '''Notes:''' Dosages were 0.625 mg/day CEEs and 2.5 mg/day MPA. '''Footnotes:''' a = Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer. b = A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes. c = Not included in Global Index. * = Nominal confidence intervals unadjusted for multiple looks and multiple comparisons. '''Sources:''' <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
|}<noinclude>
==References==
{{Reflist}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Template:Man/OpenBSD

2018-10-04T04:58:21Z

84.250.17.211: Enable HTTPS url

{{#switch:{{{3}}}
|attrib=[[OpenBSD]] {{#switch:{{{1}}} 
|1=General Commands
|2=System Calls
|3=Library Functions
|4=Kernel Interfaces
|5=File Formats
|6=Games
|7=Miscellaneous Information
|8=System Manager's
|9=Kernel Developer's}} [[man page|Manual]]
|url=https://man.openbsd.org/?query={{{2}}}&sec={{{1}}}
|display_section={{{1}}}}}<noinclude>

</noinclude>

Template:Redirect category shell/doc

2018-04-19T00:20:15Z

84.250.17.211: Replace "important" Template:Mbox with Template:Caution (where Template:Important is a redirect to). "For messages indicating e.g. that errors or misuse may have wide repercussions.", according to Template:Notice and warning templates.

{{Documentation subpage}}

{{Caution|text={{red|'''Important – Please Read''!'' {{maroon|This template should not be applied by bot, nor should it be used without parameters ''unless you want to learn how to categorize redirects''. This template is a ''learning tool'' to help editors who want to learn how to categorize redirects. ''Only'' those editors who intend to return to the redirect to learn which rcats to use should apply this template without parameters, or with an empty first parameter''!''}}'''}}}}
<includeonly>{{High-risk| 640000+ }}</includeonly>
{{hatnote|This template supplements the redirect categorization done by adding rcats individually to redirects and by past usage of the now deprecated {{tl|This is a redirect}} template. Its creation and usage is the direct result of [[Template talk:This is a redirect|discussion]]s about the benefits and the shortcomings of the ''This is a redirect'' template.}}

{{Substitution|not|nor should this template and most redirect category (rcat) templates be used to tag [[Wikipedia:Soft redirects|soft redirects]]. ''[[:Template:Wikidata redirect|Exception]]''}}
{{#ifeq:{{SUBPAGENAME}}|sandbox|{{template shortcut|Rcat shell/sandbox}}|{{template shortcut|Redirect shell|Rcat shell|RCAT shell|Rcatsh|Redr}}}}

This template is similar to {{tl|WikiProject banner shell}} in that it may be used to add one or more appropriate redirect category ([[WP:RCAT|rcat]]) templates, along with their parameters, to redirects. Additionally, this template ''automatically'' senses, describes, categorizes and changes [[WP:PP|protection levels]] when appropriate. A third important function is to help editors learn more about redirect categorization by use of the {{c|Miscellaneous redirects|manifold sort}}. For more information see the page below and the [[WP:TMR|main rcat '''index''']].

__TOC__
==Purpose==
As with the ''This is a redirect'' template, this template is based on a [[Wikipedia talk:WikiProject Redirect/Archive 1#New meta-template(s) idea|proposal]] to standardize [[wp:redirect templates|redirect templates]] (rcats). Its basic purpose is to simplify the process of tagging and categorizing redirects.

Like the ''This is a redirect'' template, this shell template is also able to help newer contributors learn the redirect category system. Details of this part of the purpose of this shell template may be found in the [[#When used alone|When used alone]] section below.

Protection levels are automatically detected by this template by use of {{tl|pp-protected}} and {{tl|pp-move}}. When edit protection or move protection (or both) is applied to a redirect that has been tagged with this template, the protection level is automatically detected, and the redirect will be tagged with a protection rcat and sorted to the appropriate protection-related category(ies). When protection is altered or removed, then the protection-related rcats and category(ies) will also be (automatically) changed or removed from the redirect.

This template can categorize and display the text (with parameters) of any number of rcats that are needed (usually from one to seven). 
<ref name="mbox" group="Mbox note">When the wikimarkup code of this template is opened, it is seen that this is an "mbox-based" template. "Mbox" stands for "multi namespace message box", which is a meta-[[Help:A quick guide to templates|template]] that works in all namespaces. There can be a problem with this mbox unless editors are careful to place ''Redirect category shell'' '''on its own line at the ''very beginning of the line'''''. If this is done then all is well; if this is not done, then [[HTML Tidy]] may interfere with the mbox and cause this template to appear in an abnormal and unexpected manner when saved. So be careful where you leave this template placed in a redirect's Edit screen, take another look at the above [[#goodread|readability guide]], and be sure to preview your edits – all your edits.
: '''{{green|Correct:}}'''
<pre>
#REDIRECT [[(target page)]]

{{Redirect category shell||
{{R unprintworthy}}
}}
</pre>
: '''{{red|''Not'' correct:}}'''
<pre>
#REDIRECT [[(target page)]] {{Redirect category shell||{{R unprintworthy}}}}
</pre>
: ''A blank line is usually placed between the redirect target and this template to make the "Edit" screen easier to read.''</ref>
<ref name="printworthiness" group="Printworthiness note">Where the [[WP:printworthiness|printworthiness]] of a [[WP:mainspace|mainspace]] redirect is concerned, there are three kinds of [[WP:RCAT|rcat]]s:
# those that populate the {{c|Printworthy redirects}} category by default,
# those that populate the {{c|Unprintworthy redirects}} category by default, and
# those that do not default to either of the above, and which leave it to the editor to decide based upon best knowledge whether or not a mainspace redirect is suitable for a printed or DVD version of ''Wikipedia''.
At present, those that are types 1 and 2 will populate the appropriate printworthiness category, however the notice will not appear within the mbox of this template unless either {{tl|R printworthy}} or {{tl|R unprintworthy}} is listed as an rcat within this template. For example, if a redirect is tagged with:
<pre>
{{Redirect category shell|
{{R from ambiguous term}}
}}
</pre>
...then the hidden categories populated will be {{c|Redirects from ambiguous pages}} and {{c|Unprintworthy redirects}}, and these will appear at the bottom of the redirect page only to registered users who are logged in and who have set their preferences to see hidden categories. The mbox that will appear to all readers would look like:
{{Redirect category shell|
{{R from ambiguous term/demo|embed=yes}}
}}
If an editor wants the printworthiness category to appear in the mbox, then the redirect must be tagged as follows:
<pre>
{{Redirect category shell|
{{R from ambiguous term}}
{{R unprintworthy}}
}}
</pre>
...which produces:
{{Redirect category shell|
{{R from ambiguous term/demo|embed=yes}}
{{R unprintworthy|embed=yes}}
}}
'''''Only then''' will the printability, ''printworthy'' or ''unprintworthy'', be described within this template's mbox on the redirect page.''</ref>

==Usage==
Used by itself with no parameters, for example, {{tlc|Redirect category shell}} (and its alias {{tlc|Rcat shell}}), the template will appear as it does at the top of this page, and the redirect will populate {{Cat|Miscellaneous redirects}}. That category will also be populated if the first parameter is left empty while rcats occupy the second parameter. This is useful when an editor adds rcats and yet feels unsure that there may be at least one other rcat with category that may be used to tag the redirect. Monitors of the ''Miscellaneous redirects'' category will then help decide if another rcat(s) is needed. Then the empty first parameter may be excluded by removing either the first or second pipe. That will remove the redirect from ''Category:Miscellaneous redirects''. [[#When used alone|See below]] for more information.

This template may hold any number of different redirect category ([[WP:RCAT|rcat]]) templates, usually from one to seven. The choices for editors are listed at [[Wikipedia:Template messages/Redirect pages]] both alphabetically and by function. Any of those rcats may be used either with their full template name, e.g., '''R from alternative language''', or with an alias (shortcut redirect), which may be found in each rcat's [[WP:TDOC|documentation]].

An unnamed parameter, {{para|1}}, has been introduced in this template and works as follows:
<pre>
{{Redirect category shell|1=
{{rcat 1}}
{{rcat 2}}
{{rcat 3}}
{{rcat N}}
}}
</pre>
: ''or'' the {{code|1{{=}}}} may be omitted:
<pre>
{{Redirect category shell|
{{rcat 1}}
{{rcat 2}}
{{rcat 3}}
{{rcat N}}
}}
</pre>
As with all templates that have unnamed (numbered) parameters, the numbers and equal signs may be omitted.

"N" represents the highest number of rcats that can be used in this template, and at this point the only limit would be any wikimarkup ceiling that may exist. Usually, from one to seven rcats suffice; however, more rcats can be used if required.

The actual sequence of rcats is left to editors – there is no priority as to which rcat should be "first" and which rcats should "follow" in any particular order.

A second unnamed parameter, {{para|2}}, has also been introduced. This gives this template the same "help" functionality that is used in the ''This is a redirect'' template. If the first parameter is left "empty", then {{cat|Miscellaneous redirects}} will be populated:
<pre>
{{Redirect category shell|1=|2=
{{rcat 1}}
{{rcat 2}}
{{rcat N}}
}}
</pre>
:''or'' if a second pipe is placed directly after the first pipe, then that will accomplish the same manifold sort:
<pre>
{{Redirect category shell||
{{rcat 1}}
{{rcat 2}}
{{rcat N}}
}}
</pre>
Note the double pipe after the word "shell" above, which indicates an empty first parameter. Editors who monitor the ''Miscellaneous redirects'' category will come to the redirect and check, add or remove rcats as needed.

Also, when used by itself this template will appear as it does at the top of this page and populate the ''Miscellaneous redirects'' category:
<pre>
{{Redirect category shell}}
</pre>

{{anchor|goodread}}
This template may be added to a redirect page in the following manner:
<pre>
#REDIRECT [[(target page name)]]

{{Redirect category shell||
{{R from short name}}
{{R unprintworthy}}
}}
</pre>
: It can be noted here that the rcats can also go on the same line as the ''Redirect category shell'' template:
<pre>
#REDIRECT [[(target page name)]]

{{Redirect category shell||{{R from short name}}{{R unprintworthy}}}}
</pre>
: Again, note the double pipe after "shell" above, which indicates an empty first parameter. Leave the first parameter empty to sort a redirect to {{cat|Miscellaneous redirects}} ''in addition to'' the categories of the rcats that are used. In this case the {{c|Redirects from short names}} and {{c|Unprintworthy redirects}} categories will also be populated. Monitors of the "Miscellaneous redirects" category will help editors when needed.

Generally for good readability on the edit screen, this template is placed beginning on the third line of that screen as follows:
<pre>
Line 1: #REDIRECT [[(target page name)]]
</pre>
Line 2: {{red|(please leave this line blank for emphasis and ease of reading by editors)}}
<pre>
Line 3: {{Redirect category shell|{{R from move}}{{R to section}}{{R printworthy}}}}
</pre>
: ''See also: section titled '''[[#Mbox-based|Mbox note]]''' below.''

=== Parameters ===

In addition to the unnamed {{para|1}} and {{para|2}} parameters, there is a "hatnote" parameter, {{para|h}}, which provides an italicized TOP note when needed. For example:
<pre>
{{Redirect category shell|h=This code has not been confirmed as an [[International Air Transport Association airport code|IATA]] airport code.|
{{R from airport code}}
}}
</pre>
...uses the rcat {{tl|R from airport code}} and produces:

{{Mbox
| name = This is a redirect/rcat
| type = move
| image = none
| style = margin-top: 1.1em; border: solid 1px darkblue; border-left-width: 0.5em;
| textstyle = padding-top: 0.9em; padding-bottom: 0.9em;
| text = [[File:Symbol redirect arrow with gradient.svg|25px|link=]] '''This page is a [[Wikipedia:Redirect|redirect]]:'''
:: ''This code has not been confirmed as an [[International Air Transport Association airport code|IATA]] airport code.''
* {{R from airport code|embed=yes}}
{{Ombox|type=content|image=[[File:Stop hand orange.svg|50px]]|text={{Error|The above [[WP:RCAT|rcat]] should only be used to categorize redirects that are in the ''[[WP:main|main]]'' namespace.}}}}
''When appropriate, [[WP:PP|protection levels]] are automatically sensed, described and categorized.''
}}

:''An error box appears that illustrates what happens if an editor uses an rcat in the wrong namespace. Correct namespaces are found on individual rcat documentation pages. In addition to the error box, the redirect '''''will not''''' be sorted to the rcat's category; instead it will populate '''''{{cat|Pages with templates in the wrong namespace}}!''' ''If an error box appears when an edit is '''previewed''', then appropriate changes can be made ''before'' the redirect page is actually '''saved'''.''

==== Rcat parameters ====
In addition to this template's ability to act as a shell template for rcats, it accepts all of the parameters that rcats accept. Rcat parameters, when needed, will work in this template as follows:

<pre>
{{Redirect category shell|
{{R from plural|printworthy}}
}}
</pre>

This subdues the {{c|Unprintworthy redirects}} category to which {{tl|R from plural}} defaults and populates the {{c|Printworthy redirects}} category instead. The position an rcat holds will have no effect on the parameters of other rcats that are used to tag a redirect:

<pre style="font-size:95%;overflow:auto;">
{{Redirect category shell|
{{R from move}}
{{R from modification}}
{{R from alternative name}}
{{R from alternative language|en|es}}
{{R for convenience}}
{{R from plural|printworthy}}
{{R printworthy}}
}}
</pre>

In the above example, {{tl|R from plural}} is the sixth rcat, and its first parameter is used to change from "unprintworthy" to "printworthy". {{tl|R from alternative language}}) holds the 4th position, and its first parameter is used to house the [[Wikipedia:Template messages/Redirect language codes|ISO 639 language code]] of the source language, in this case '''<code>{{nbsp}}en{{nbsp}}</code>''' for [[English language|English]]. Its second parameter houses the language code for the targeted page, in this case '''<code>{{nbsp}}es{{nbsp}}</code>''' for the [[Spanish language]]. It does not matter if the relative position of these rcats changes for any reason, their individual parameters will continue to be effective.

If more rcat parameters are used, then they work the same way. For example, if a redirect exists that is a misspelling of a title, it can be tagged with {{tl|R from misspelling}} in the following manner:

<pre>
{{Redirect category shell|
{{R from misspelling|(correct spelling if needed)|printworthy}}
{{R printworthy}}
}}
</pre>

In this case, the rcat's ''{{para|1}}'' parameter is the correct spelling (used only if the target of the redirect is '''not''' the correct spelling). The rcat's ''{{para|2}}'' parameter can be used to change from the default "unprintworthy" categorization. Some misspellings may be helpful in a printed version of ''Wikipedia'', so the second parameter in ''R from misspelling'' above is used to subdue its default "unprintworthy" category sort, and the redirect will populate {{cat|Printworthy redirects}} instead. In this shell template, the order of the rcats will not affect the rcats' parameters. If an editor checks the page history and finds that the above redirect is also the result of a page move and inserts {{tl|R from move}} at the top of the order:

<pre>
{{Redirect category shell|
{{R from move}}
{{R from misspelling|(correct spelling)|printworthy}}
{{R printworthy}}
}}
</pre>

...the parameters of the ''R from misspelling'' rcat template will not be affected, as they may be when used in the ''This is a redirect'' template.

An example of a "printworthy misspelling" can be found at template {{tl|R from misspelling}}.

'''Another example:'''

<pre>
{{Redirect category shell|
{{R from alternative language|ja|es}}
{{R unprintworthy}}
}}
</pre>

The above code will sort the redirect into three categories:
* {{c|Redirects from Japanese-language terms}} ({{para|1|ja}}),
* {{c|Redirects to Spanish-language terms}} ({{para|2|es}}) and
* {{c|Unprintworthy redirects}}

''See the lists of [[List of ISO 639-1 codes|ISO 639-1]] and [[List of ISO 639-2 codes|ISO 639-2]] codes for two- and three-letter language codes that can be used this way. See also [[Wikipedia:Template messages/Redirect language codes]] for common codes that are already used on redirects.''

=== When used alone ===
This template is designed to help contributors who are unfamiliar with categorizing redirects by enabling them to sort redirects into the monitored {{c|Miscellaneous redirects}} category. Do not hesitate to use this important function to help with sorting redirects to correct and appropriate categories.

There are two ways to sort a redirect into the ''Miscellaneous redirects category''. When this template is used without any rcats, it will perform the miscellaneous sort:

{{tlx|Redirect category shell}}...
{{Redirect category shell|nocat=true}}

Also, if one or more rcats are known, but an editor is unsure that there might be one or more ''other'' rcats that are needed, then leave the first parameter blank (type two pipes together → <code>||</code>):
<pre>
{{Redirect category shell||
{{R from subtopic}}
{{R printworthy}}
}}
</pre>

{{Redirect category shell|nocat=true||
{{R from subtopic|embed=yes}}
{{R printworthy|embed=yes}}
}}

Monitors of the ''Miscellaneous redirects'' category will check the redirect, add other rcats if needed and then remove the empty first parameter.

==Comparison==
[[Template:Redirect category shell/Comparison]] shows the difference in the appearance of text between when individual rcats are used and when this template is used.

==Other templates==
This template may also carry and hold other templates within it. Even the {{tl|DEFAULTSORT}} magic word and a [[WP:sort key|sort key]] may be used either inside this template or below it. Another template commonly used within the ''Rcat shell'' template is {{tl|Italic title}} and its shortcut {{tl|ital}} to format titles in italics. Some rcats such as {{tl|R from book}} and {{tl|R from film}} automatically format the redirect names in italics. Any appropriate template may be used within this shell template in the following manner:
<pre>
{{Redirect category shell|
{{R from move}}
{{R from alternative name}}
{{Italic title}}
{{DEFAULTSORT:Hobbit, The}}
}}
</pre>

==Notes==
{{anchor|Mbox-based}}
'''Mbox note'''
{{Reflist|group="Mbox note"}}
'''Printworthiness note'''
{{See also|Wikipedia:Printability}}
{{Reflist|group="Printworthiness note"}}

==See also==
* {{tl|Talk page of a redirect}}, to "[[WP:SRD|soft]]" redirect a [[WP:subject page|subject page]]'s talk page that has already been created '''''and given content''''' (project banners, deletion/merge notices, discussions)
* [[Wikipedia:Protection policy]], for questions related to this template's ability to detect protection levels
* [[Wikipedia:Template messages/Redirect pages]], a functional and an alphabetical index of rcats
* [[Wikipedia:WikiProject Redirect/Style guide|WikiProject Redirect/Style guide]]

{{R template index}}

<includeonly>{{sandbox other||

[[Category:WikiProject Redirect templates|Redirect category shell]]
[[Category:Redirect templates| ]]

}}</includeonly>

Template:Latest preview software release/Lynx

2018-04-19T00:07:42Z

84.250.17.211: Update to 2.8.9dev.17, release date 2018-03-21, update reference access date

{{LPR
| article = Lynx
| latest_release_version = 2.8.9dev.17<ref>{{cite web|url=http://lynx.invisible-island.net/current/CHANGES.html|title=Changes since Lynx 2.8 release|website=lynx.invisible-island.net|accessdate=19 April 2018}}</ref>
| latest_release_date = {{release date and age|2018|03|21|df=yes}}
}}<noinclude>

➔ Back to article "'''[[Lynx (web browser)]]'''"

[[Category:Latest preview software release templates|Lynx]]

</noinclude>

Template:Cleanup list/doc

2018-04-14T04:40:38Z

84.250.17.211: Add Template:Improve documentation, date=April 2018: At least the date parameter is missing, others?

{{Documentation subpage}}
{{Improve documentation|date=April 2018}}

==Usage==

* This template will categorise tagged articles into [[:Category:Wikipedia list cleanup]].
* This [[Wikipedia:Template|template]] is a [[Wikipedia:Avoid self-references|self-reference]].
* Please do not [[Wikipedia:Subst|subst:]] this template.
* For use in sections, use {{tlx|Cleanup list|section}}

{{tl|Cleanup list}} is for poorly trimmed lists, while {{tl|Example farm}} is for poorly trimmed articles, including prose.

==Redirects==
#{{tl|Cleanup list}}
#{{tl|Cleanuplist}}
#{{tl|Cleanup-list}}
#{{tl|CleanupList}}
#{{tl|List-cleanup}}
#{{tl|Cleanup-laundry}}
#{{tl|Inclusion}}

==See also==
* [[Wikipedia:Embedded lists]], style guideline
* {{tlx|List missing criteria}} for stand-alone lists
* {{tlx|Prose}}, to indicate lists that should be converted to prose
* {{tlx|Expand list}} – for use where a list is too short/incomplete
* {{tlx|List to table}} – for use where a table would be better than a list
* {{tlx|Create list}} – for when a list is needed instead of prose
{{collapse top|left=y|Other trivia-related templates}}
{{Trivia templates see-also}}
{{collapse bottom}}
* [[Wikipedia:Template messages/Cleanup]]
* [[Wikipedia:Template messages/Sources of articles]]

<includeonly>
[[Category:Coherency templates]]
[[Category:List cleanup maintenance templates]]
</includeonly>

Template:Available

2018-04-13T02:52:24Z

84.250.17.211: Undid revision 836172669 by 84.250.17.211 (talk): Okay, I'll throw my hands up in the air and let someone else figure it out

<noinclude>{{Being deleted|2018 April 5|Red_and_green_table_highlights|merge=Template:Yes}}</noinclude>{| class="wikitable"
|-
|</noinclude>style="background: #90ff90; color: black; vertical-align: middle; text-align: {{{align|center}}}; {{{style|}}}" class="table-yes"|{{{1|Available}}}<noinclude>
|}
{{Documentation|Template:Table cell templates/doc}}
</noinclude>

Template:Available

2018-04-13T02:51:34Z

84.250.17.211: Undid revision 836172569 by 84.250.17.211 (talk): Try again, caches

<noinclude>{{Being deleted|2018 April 5|Red_and_green_table_highlights|merge=Template:Yes}}</noinclude>
<noinclude>{| class="wikitable"
|-
|</noinclude>style="background: #90ff90; color: black; vertical-align: middle; text-align: {{{align|center}}}; {{{style|}}}" class="table-yes"|{{{1|Available}}}<noinclude>
|}
{{Documentation|Template:Table cell templates/doc}}
</noinclude>

Template:Available

2018-04-13T02:50:36Z

84.250.17.211: Undid revision 836172513 by 84.250.17.211 (talk): That blew up documentation (and more?)

Template:Available

2018-04-13T02:50:04Z

84.250.17.211: Add missing newline and noinclude to fix template

Template:Cleanup red links/doc

2018-03-24T23:10:20Z

84.250.17.211: /* Usage */ Convert to preformatted text

{{Documentation subpage}}


===When to use ===
Add this to the top of an article whenever:
* There are too many red links for this article.
* One or more of the links present (regardless of number) are inappropriate for any reason.
* Red links are generally not included in either [[WP:LAY#See also|See also]] sections or in [[WP:NAVBOX#Properties|navigational boxes]], or pointed to with templates such as {{tlx|Main}} or {{tlx|Further2}}, since these navigation aids are intended to help readers find existing articles. The exception is redlinks in navboxes where the articles are part of a series or a whole set, e.g. a navbox listing successive elections, referendums, presidents, sports league seasons, etc.

Please consider "weeding the link farm" yourself, rather than using this tag to ask someone else to do it. Don't forget to remove this template when the concerns appear to have been resolved. You can clear red links in an article systematically by running the following [[User:AlexTheWhovian/script-redlinks|script]].

=== Usage ===
For articles, use:
<nowiki>{{</nowiki>Cleanup red links|date={{CURRENTMONTHNAME}} {{CURRENTYEAR}}}}

To flag an individual section, use:
<nowiki>{{Cleanup red links|section|date=</nowiki>{{CURRENTMONTHNAME}} {{CURRENTYEAR}}<nowiki>}}</nowiki>

This template will categorize tagged articles into [[:Category:Wikipedia red link cleanup]].

* This [[Wikipedia:Template|template]] is a [[Wikipedia:Avoid self-references|self-reference]].
* Please do not [[Wikipedia:Substitution|substitute]] this template.

=== See also ===
* [[Wikipedia:Red link]]
* [[Wikipedia:Template messages/Cleanup]]

<includeonly>

[[Category:Exclude in print]]
[[Category:Internal link maintenance templates|{{PAGENAME}}]]
[[Category:Cleanup templates|{{PAGENAME}}]]
[[el:Κόκκινοι σύνδεσμοι επιμέλεια]]
</includeonly>

Template:Di-no license/doc

2018-03-22T23:15:16Z

84.250.17.211: /* See also */ Replace nld with nsd: nld is this template

{{Documentation subpage}}

{{twinkle standard installation}}
{{Speedy deletion templates}}
===Usage===
Don't use this template directly. Instead, use:
<pre>{{subst:nld}}</pre>
This will add {{tlc|di-no license}}, with the <code>date=</code> parameter already filled in.
{{in category|Wikipedia files with unknown copyright status}}

===See also===
* {{tlsp|nsd}}

<includeonly>
[[Category:File deletion templates|{{PAGENAME}}]]
[[Category:Deletion tags|{{PAGENAME}}]]

</includeonly>

Template:Latest stable software release/mpv (media player)

2017-12-26T00:45:45Z

84.250.17.211: Add a third-party reference (Phoronix)

{{LSR
| article = mpv (media player)
| latest release version = 0.28.0
| latest release date = {{Start date and age|2017|12|24}}<ref name="phoronix-mpv-player-0.28-released">{{Cite news |title=MPV Player 0.28 Adds Initial Vulkan Support |url=https://www.phoronix.com/scan.php?page=news_item&px=MPV-Player-0.28-Released |last1=Larabel |first1=Michael |date=2017-12-25 |website=[[Phoronix]] |publisher=Phoronix Media |archive-url=https://web.archive.org/web/20171226004412/https://www.phoronix.com/scan.php?page=news_item&px=MPV-Player-0.28-Released |archive-date=2017-12-26 |dead-url=no |access-date=2017-12-26}}</ref><ref name="gh-mpv-0.28.0">{{Cite web |title=Release v0.28.0 |url=https://github.com/mpv-player/mpv/releases/tag/v0.28.0 |last1=Herkt |first1=Martin |date=2017-12-14 |website=mpv-player/mpv (source code repository) |publisher=GitHub |archive-url=https://web.archive.org/web/20171226003947/https://github.com/mpv-player/mpv/releases/tag/v0.28.0 |archive-date=2017-12-26 |dead-url=no |access-date=2017-12-26}}</ref>
}}<noinclude>
➔ Back to article "'''[[mpv (media player)]]'''"

{{Template reference list}}

[[Category:Latest stable software release templates|mpv]]
</noinclude>

Template:Latest stable software release/mpv (media player)

2017-12-26T00:40:58Z

84.250.17.211: Update latest release version to 0.28.0 (2017-12-24), referenced

{{LSR
| article = mpv (media player)
| latest release version = 0.28.0
| latest release date = {{Start date and age|2017|12|24}}<ref name="gh-mpv-0.28.0">{{Cite web |title=Release v0.28.0 |url=https://github.com/mpv-player/mpv/releases/tag/v0.28.0 |last1=Herkt |first1=Martin |date=2017-12-14 |website=mpv-player/mpv (source code repository) |publisher=GitHub |archive-url=https://web.archive.org/web/20171226003947/https://github.com/mpv-player/mpv/releases/tag/v0.28.0 |archive-date=2017-12-26 |dead-url=no |access-date=2017-12-26}}</ref>
}}<noinclude>
➔ Back to article "'''[[mpv (media player)]]'''"

{{Template reference list}}

[[Category:Latest stable software release templates|mpv]]
</noinclude>

Template:Copyvio links

2017-12-21T20:19:10Z

84.250.17.211: Say "works" instead of "publications", per the latter "such works"

{{SAFESUBST:<noinclude />#invoke:Unsubst||date=__DATE__|$B={{Ambox
| name = Copyvioel
| type = content
| image = [[File:Copyright-problem.svg|40px|alt=|link=]]
| issue = This {{{1|article or section}}} may contain '''[[Wikipedia:Copyrights#Linking to copyrighted works|links to copyright infringing works]]'''.
| all = {{#ifeq:{{yesno-no|{{{nocat|}}}}}|yes||Articles containing links to copyright violations}}
| fix = Please edit this article to remove links to such works.
| date = {{{date|}}}
}}}}<noinclude>
{{Documentation
| content = {{Improve documentation|date=November 2017}}
}}
[[Category:Copyright maintenance templates]]
</noinclude>

Template:Copyvio links

2017-12-21T20:17:08Z

84.250.17.211: Undid revision 812395079 by ViperSnake151 (talk): WP:BOLD (again), no responses to talkback or comments at User talk:84.250.17.211

{{SAFESUBST:<noinclude />#invoke:Unsubst||date=__DATE__|$B={{Ambox
| name = Copyvioel
| type = content
| image = [[File:Copyright-problem.svg|40px|alt=|link=]]
| issue = This {{{1|article or section}}} may contain '''[[Wikipedia:Copyrights#Linking to copyrighted works|links to copyright infringing publications]]'''.
| all = {{#ifeq:{{yesno-no|{{{nocat|}}}}}|yes||Articles containing links to copyright violations}}
| fix = Please edit this article to remove links to such works.
| date = {{{date|}}}
}}}}<noinclude>
{{Documentation
| content = {{Improve documentation|date=November 2017}}
}}
[[Category:Copyright maintenance templates]]
</noinclude>

Template:Copyvio links

2017-11-27T11:54:13Z

84.250.17.211: Word-replace "material" to "publications": Neutral point of view

{{SAFESUBST:<noinclude />#invoke:Unsubst||date=__DATE__|$B={{Ambox
| name = Copyvioel
| type = content
| image = [[File:Copyright-problem.svg|40px|alt=|link=]]
| issue = This {{{1|article or section}}} may contain '''[[Wikipedia:Copyrights#Linking to copyrighted works|links to copyright infringing publications]]'''.
| all = {{#ifeq:{{yesno-no|{{{nocat|}}}}}|yes||Articles containing links to copyright violations}}
| fix = Please edit this article to remove links to such works.
| date = {{{date|}}}
}}}}<noinclude>
{{Documentation
| content = {{Improve documentation|date=November 2017}}
}}
[[Category:Copyright maintenance templates]]
</noinclude>

Template:Copyvio links

2017-11-27T11:49:28Z

84.250.17.211: Create inline documentation for a maintenance tag: Template:Improve documentation (missing documentation), date=November 2017

{{SAFESUBST:<noinclude />#invoke:Unsubst||date=__DATE__|$B={{Ambox
| name = Copyvioel
| type = content
| image = [[File:Copyright-problem.svg|40px|alt=|link=]]
| issue = This {{{1|article or section}}} may contain '''[[Wikipedia:Copyrights#Linking to copyrighted works|links to copyright infringing material]]'''.
| all = {{#ifeq:{{yesno-no|{{{nocat|}}}}}|yes||Articles containing links to copyright violations}}
| fix = Please edit this article to remove links to such works.
| date = {{{date|}}}
}}}}<noinclude>
{{Documentation
| content = {{Improve documentation|date=November 2017}}
}}
[[Category:Copyright maintenance templates]]
</noinclude>